

# A scoring system for thromboembolic risk assessment in surgery, developed by the Polish Working Group, on the basis of the scoring system developed by Joseph Caprini

Skala punktowa opracowana przez Polską Grupę Roboczą na podstawie skali Josepha Capriniego dotycząca oceny stopnia zagrożenia rozwoju powikłań zakrzepowo-zatorowych w chirurgii

by the Polish Working Group (Polska Grupa Robocza)

---

## Abstract

**Background.** Thromboembolic risk assessment is crucial for the appropriate prescription of thromboprophylaxis. Such assessments are facilitated by scoring systems. We aimed to develop a scoring system intended for surgeons, which would allow them to assess this risk in a rapid, reproducible and reliable manner and therefore to use the most effective thromboprophylaxis.

**Material and methods.** The Polish Working Group was established to draw up a scoring system for thromboembolic risk assessment. Joseph Caprini's scoring system was the starting point and model for the Group's efforts, which were supplemented by bibliographical data and the members' own experience. The obtained total score forms the basis for including the patient in a particular risk group, which is associated with a particular thromboprophylaxis regimen.

**Results and conclusions.** The scoring system is a simple tool that could gain widespread acceptance among surgeons representing various specialties. As the scoring system has not been verified in clinical practice, it may only be used supportively for now in the assessment of venous thromboembolism.

**Key words:** scoring system, The Polish Working Group, thromboembolic complications, hospitalisation, surgical ward

## Streszczenie

**Wstęp.** Ocena zagrożenia powikłaniami zakrzepowo-zatorowymi stanowi podstawę odpowiedniej ordynacji profilaktyki przeciwzakrzepowej. Narzędziem ułatwiającym dokonanie tej oceny jest skala punktowa. Celem pracy było przygotowanie skali punktowej adresowanej do chirurgów, która umożliwi szybką, powtarzalną i jednoznaczną ocenę takiego ryzyka oraz zastosowanie najskuteczniejszej profilaktyki przeciwzakrzepowej.

**Materiał i metody.** W celu przygotowania skali punktowej służącej ocenie zagrożenia związanego z ryzykiem wystąpienia powikłań zakrzepowo-zatorowych powołano Polską Grupę Roboczą.

Punktem wyjściowym oraz wzorem do opracowania chirurgicznej skali punktowej stała się skala Josepha Capriniego. Podczas prac korzystano z danych z piśmiennictwa oraz doświadczenia własnego członków Polskiej Grupy Roboczej. Suma uzyskanych w skali punktów stanowi podstawę włączenia chorych do grupy ryzyka, co wiąże się z zastosowaniem rekomendowanej formy profilaktyki.

---

Address for correspondence:

Prof. dr hab. med. Witold Tomkowski

Oddział Intensywnej Terapii Pneumonologiczno-Kardiologicznej

Instytut Gruźlicy i Chorób Płuc w Warszawie

ul. Płocka 26, 01–138 Warszawa

e-mail: [w.tomkowski@igjchp.edu.pl](mailto:w.tomkowski@igjchp.edu.pl)

*Wyniki i wnioski.* Zaprezentowana skala punktowa może stanowić proste narzędzie powszechnie stosowane przez lekarzy dyscyplin zabiegowych. Skali dotychczas nie sprawdzano w praktyce klinicznej, zatem stanowi ona jedynie formę pomocy w ocenie ryzyka rozwoju żyłnej choroby zakrzepowo-zatorowej.

**Słowa kluczowe:** skala punktowa, Polska Grupa Robocza, powikłania zakrzepowo-zatorowe, hospitalizacja, oddział zabiegowy

Acta Angiol 2011; 17, 1: 49–76

---

## Introduction

Thromboembolic risk assessment is crucial for the appropriate prescription of thromboprophylaxis. Scoring systems are a rapid and relatively simple method to assess this risk. It seems that the development of a scoring system by the Polish scientific community, which would be specifically intended for Polish surgeons, is extremely important and well justified.

Although thromboprophylaxis has gained the place it deserves in the majority of Polish surgical wards, serious mistakes and acts of negligence continue to be observed in this area in the form of a failure to initiate appropriate forms of thromboprophylaxis in patients found to have significant risk of VTE, including fatal pulmonary embolism (PE). It should be stressed that the acts of negligence and errors in this area mainly consist of insufficient duration of prophylaxis, prescribing inappropriate doses of drugs, and the erroneous assessment of the risk of thromboembolic complications.

It seems obvious that the development of a scoring system that could be used in surgical specialties will enable practicing surgeons to perform a rapid, reproducible, and reliable assessment of thromboembolic risk and to initiate the appropriate and most effective form of thromboprophylaxis recommended by the Polish Working Group.

## Material and methods

The Polish Working Group was established to develop a surgical scoring system for the assessment of thromboembolic risk. The Group consisted of the most renowned Polish specialists in the field of venous thromboembolism (VTE) and the most renowned representatives of the Polish surgical community (the names of the experts are listed at the end of the paper). The scoring system proposed by Joseph Caprini was the starting point and model for the development of the surgical scoring system [1].

The evaluation of the risk factors, their weight, the degree of danger, and the efficacy of the individual forms of thromboprophylaxis were based on the review of bibliography (following the principles of evidence-based medicine) [2–583] and on the mem-

## Wstęp

Ocena stopnia zagrożenia powikłaniami zakrzepowo-zatorowymi stanowi podstawę odpowiedniej ordynacji profilaktyki przeciwzakrzepowej. Narzędziem, dzięki któremu w szybki i stosunkowo prosty sposób można ocenić to zagrożenie, są skale punktowe. Wydaje się, że przygotowanie przez polskie środowisko naukowe takiej skali zaadresowanej do polskich chirurgów jest niezwykle ważne i celowe.

Choć profilaktyka przeciwzakrzepowa uzyskała odpowiednią rangę na większości polskich oddziałów zabiegowych, to jednak stale w tej dziedzinie zdarzają się rażące błędy i zaniedbania polegające na zaniechaniu stosowania odpowiedniej formy profilaktyki przeciwzakrzepowej u chorych, u których stwierdza się poważne ryzyko rozwoju żyłnej choroby zakrzepowo-zatorowej ze śmiertelnym zatorom tętnicy płucnej włącznie. Warto podkreślić, że zaniedbania i błędy w tym zakresie polegają głównie na zbyt krótkim stosowaniu profilaktyki, zleceniu nieodpowiednich dawek leków, a także na błędnej ocenie stopnia zagrożenia rozwojem powikłań zakrzepowo-zatorowych.

Wydaje się oczywiste, że przygotowanie skali punktowej, którą można wykorzystać w dyscyplinach zabiegowych, ułatwi polskim chirurgom praktykom szybką, powtarzalną i jednoznaczną ocenę stopnia zagrożenia rozwojem powikłań zakrzepowo-zatorowych oraz zastosowanie rekomendowanej przez Polską Grupę Roboczą odpowiedniej, najskuteczniejszej formy profilaktyki przeciwzakrzepowej.

## Materiał i metody

Do prac nad przygotowaniem chirurgicznej skali punktowej powołano Polską Grupę Roboczą (nazwiska ekspertów podano na końcu pracy) składającą się z najwybitniejszych polskich specjalistów zajmujących się żylną chorobą zakrzepowo-zatorową oraz najwybitniejszych przedstawicieli polskiego środowiska chirurgicznego. Punktem wyjściowym oraz wzorem do opracowania chirurgicznej skali punktowej stała się skala Josepha Capriniego [1].

Oceniając czynniki ryzyka, ich moc, stopień zagrożenia oraz skuteczność poszczególnych form profilaktyki przeciwzakrzepowej wykorzystano dane z piśmiennictwa, czyli

bers' own experience (following the principles of eminence-based medicine). Individual decisions regarding the assignment of specific numbers of points to risk factors and the specific recommendations contained, therefore, an element based on bibliography and an element based on the clinical experience of the Polish Working Group members.

At the plenary meeting of the Polish Working Group, which took place in Warsaw, Poland, the members drew up an outline of the scoring system. Then, through a discussion, which was carried out by means of email, the members and the corresponding members all prepared the final version of the Polish Working Group scoring system presented in this paper.

The individual acquired and congenital risk factors and the individual clinical situations were assigned specific numbers of points. The total score is the basis of classifying the patient in the appropriate risk group, which in turn is associated with using a specific form of thromboprophylaxis recommended by the Polish Working Group.

## Results

### Venous thromboembolism risk assessment

Each factor represents 1 point:

- age 41–60 years;
- minor surgery (< 60 minutes);
- history of major surgery (< 1 month);
- varicose veins (C<sub>3</sub>–C<sub>6</sub>);
- history of inflammatory bowel disease;
- leg oedema;
- obesity [body mass index (BMI) > 30 kg/m<sup>2</sup>];
- acute myocardial infarction (< 1 month);
- congestive heart failure (exacerbation < 1 month);
- severe lung disease, including pneumonia (< 1 month);
- chronic obstructive pulmonary disease (COPD);
- medical co-morbidities: a bed-ridden patient;
- lower limb in a plaster cast or brace;
- central venous access;
- history of superficial vein thrombosis.

Each factor represents 2 points:

- age 60–74 years;
- major surgery (> 60 minutes);
- arthroscopic surgery;
- laparoscopic surgery (> 60 minutes);
- previous malignancy;
- sepsis (< 1 month);
- morbid obesity (BMI > 40 kg/m<sup>2</sup>);
- lower-risk thrombophilia (patients with heterozygous factor V Leiden or prothrombin gene mutation, factor VIII activity exceeding 150%);

zastosowano medycynę opartą na dowodach (*evidence based medicine*) [2–583], a także wykorzystano doświadczenie kliniczne członków Polskiej Grupy Roboczej (*eminence based medicine*). Poszczególne decyzje dotyczące przyporządkowania określonych punktów czynnikom ryzyka oraz konkretne rekomendacje zawierały więc w sobie element oparty zarówno na piśmiennictwie, jak i doświadczeniu klinicznym członków Polskiej Grupy Roboczej.

Na posiedzeniu plenarnym Polskiej Grupy Roboczej, które odbyło się w Warszawie, jej członkowie przygotowali wstępny zarys skali punktowej. Następnie na drodze debaty przeprowadzonej za pośrednictwem poczty elektronicznej członkowie oraz członkowie korespondencyjni przygotowali ostateczny kształt skali punktowej Polskiej Grupy Roboczej prezentowany w tym artykule.

Poszczególnym nabytym lub wrodzonym czynnikom ryzyka oraz sytuacjom klinicznym przyporządkowano odpowiednią liczbę punktów. Ich suma stanowi podstawę włączenia chorego do odpowiedniej grupy ryzyka, co z kolei wiąże się z zastosowaniem rekomendowanej przez Polską Grupę Roboczą formy profilaktyki.

## Wyniki

### Ocena ryzyka żyłnej choroby zakrzepowo-zatorowej

Każdy czynnik oznacza 1 punkt:

- wiek 41–60 lat;
- mały zabieg chirurgiczny (< 60 minut);
- duży zabieg chirurgiczny w wywiadzie (< 1 miesiąc);
- żyłki kończyn dolnych (C<sub>3</sub>–C<sub>6</sub>);
- choroby zapalne jelit w wywiadzie;
- obrzęki kończyn dolnych;
- otyłość [wskaznik masy ciała (BMI) > 30 kg/m<sup>2</sup>];
- ostry zawał serca (< 1 miesiąc);
- zastoinowa niewydolność serca (zaostrenie < 1 miesiąc);
- ciężkie choroby płuc, w tym zapalenie płuc (< 1 miesiąc);
- przewlekła obturacyjna choroba płuc (POChP);
- obciążenia internistyczne — chory unieruchomiony w łóżku;
- unieruchomienie kończyny dolnej w gipsie lub ortezie;
- cewnik w żyłę centralnej;
- przebyte zapalenie zakrzepowe żył powierzchownych.

Każdy czynnik oznacza 2 punkty:

- wiek 60–74 lat;
- duży zabieg chirurgiczny (> 60 minut);
- zabieg artroskopowy;
- chirurgia laparoskopowa (> 60 minut);
- przebyta choroba nowotworowa;

— family history of deep vein thrombosis (DVT) or pulmonary embolism.

Each factor represents 3 points:

- age 75 years or more;
- major surgery lasting more than 3 hours;
- BMI > 50 kg/m<sup>2</sup>;
- history of DVT or PE;
- higher-risk thrombophilia (patients with homozygous factor V Leiden or prothrombin 20210A gene mutation, antithrombin [AT] deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies);
- complex thrombophilia (co-existence of genetic defects);
- heparin-induced thrombocytopenia (HIT).  
Each factor represents 5 points:
  - major lower extremity arthroplasty;
  - hip, pelvis, or leg fracture;
  - ischaemic stroke (< 1 month);
  - multi-organ injury (< 1 month);
  - acute spinal cord injury with paralysis (< 1 month);
  - DVT or PE during treatment;
  - repeat surgery;
  - surgery in a patient with active cancer.

#### **Risk factors to be additionally considered in women**

Each factor represents 1 point:

- history of intrauterine death;
- history of habitual abortion (> 3);
- premature birth with pregnancy-induced hypertension or history of intrauterine growth restriction.  
Each factor represents 2 points:
  - hormonal contraception or hormone replacement therapy (HRT);
  - pregnancy or postpartum (up to 6 weeks).

#### **Scoring, assignment of the total score to the risk group, and the Polish Working Group recommendations**

Below are the total score values/ranges along with the corresponding levels of thromboembolic risk and the recommended measures:

- 0 to 1 (low risk): Early ambulation is recommended;
- 2 (moderate risk): Pharmacological prophylaxis is recommended according to the manufacturer's indications and directions;
- 3 (high risk): Pharmacological prophylaxis is recommended according to the manufacturer's directions. If contraindications to pharmacological prophylaxis are identified, physical prophylaxis is recommended;

- posocznica (< 1 miesiąc);
- duża otyłość (BMI > 40 kg/m<sup>2</sup>);
- trombofilia mniejszego ryzyka (heterozygotyczna postać czynnika V Leiden lub mutacji genu protrombiny, wzrost aktywności czynnika VIII > 150%);
- zakrzepica żył głębokich lub zator tętnicy płucnej w wywiadzie rodzinnym.

Każdy czynnik oznacza 3 punkty:

- wiek powyżej 75 lat;
- duży zabieg chirurgiczny (> 3 godzin);
- BMI > 50 kg/m<sup>2</sup>;
- przebyta zakrzepica żył głębokich lub zator tętnicy płucnej;
- trombofilia większego ryzyka (homozygotyczna postać czynnika V Leiden lub mutacji 20210A genu protrombiny, niedobór AT, białka C, białka S, obecność przeciwciał antyfosfolipidowych);
- trombofilia złożona (współistnienie genetycznie uwarunkowanych defektów);
- małopłytkowość indukowana heparyną (HIT).  
Każdy czynnik oznacza 5 punktów:
  - protezoplastyka dużych stawów kończyn dolnych;
  - złamanie biodra, miednicy lub kończyny dolnej (< 1 miesiąc);
  - udar niedokrwienny mózgu (< 1 miesiąc);
  - uraz wielonarządowy (< 1 miesiąc);
  - ostry uraz rdzenia kręgowego z porażeniem (< 1 miesiąc);
  - zakrzepica żył głębokich lub zator tętnicy płucnej w trakcie leczenia;
  - reoperacja;
  - zabieg chirurgiczny u chorego z aktywną chorobą nowotworową.

#### **Czynniki ryzyka, które należy uwzględnić u kobiet**

Każdy czynnik oznacza 1 punkt:

- wewnątrzmaciczne obumarcie płodu w wywiadzie;
- poronienia nawykowe (> 3) w wywiadzie;
- przedwczesny poród z nadciśnieniem indukowanym ciążą lub wewnątrzmaciczne zahamowanie wzrostu płodu w wywiadzie.

Każdy czynnik oznacza 2 punkty:

- antykoncepcja hormonalna lub hormonalna terapia zastępcza (HTZ);
- ciąża lub połóg (do 6 tygodni).

#### **Punktacja i przyporządkowanie uzyskanej sumy do grupy ryzyka oraz rekomendacje Polskiej Grupy Roboczej**

Jeśli suma uzyskanych punktów mieści się w przedziale przedstawionym poniżej, to ryzyko rozwoju powikłań zakrzepowo-zatorowych ocenia się jako:

— 4 or more (very high risk): A combination of pharmacological prophylaxis and intermittent pneumatic compression of the legs is recommended.

In each case, before the initiation of thromboprophylaxis, the presence of contraindications should be checked. If contraindications to pharmacological prophylaxis exist, the use of physical methods is recommended [62, 66–73, 75–92, 193, 199, 204, 328–333, 361–365, 392, 401, 415, 487, 488, 491, 506–509, 512].

It is recommended that prolongation of primary thromboprophylaxis be considered in selected patients until 28 days post-discharge with the use of once-daily subcutaneous low-molecular-weight heparin (LMWH), in patients following surgery for cancer or following a surgical procedure associated with a high risk of VTE, unless it is associated with an unacceptably high risk of haemorrhagic complications [152, 170].

Pharmacological prophylaxis is defined as the use of unfractionated heparin [19–21, 45, 54, 74, 181–183, 191, 200, 201, 259–261, 389, 467, 489, 492–494, 558], LMWH [23–42, 45, 54, 63–65, 74, 300–301, 304, 325, 344, 345–351, 366–371, 374–375, 382–384, 427, 431, 442, 448, 450–456, 458–463, 471, 474–476, 561–562, 565], pentasaccharides [91, 106, 292, 351–356, 423], oral direct inhibitors of factor Xa and factor II [573–583], according to the label.

The use of acetylsalicylic acid or other antiplatelet drugs is not recommended in the prophylaxis of VTE [93–104, 194, 294].

## Discussion

The assignment of an appropriate number of points to risk factors or clinical situations always raises certain controversies [2–17]. They stem, for instance, from quite an arbitrary division of surgical procedures relative to their duration. It seems, however, that the method of assigning specific numbers of points to specific durations of surgery is justified and reflected by the clinical experience of the Polish Working Group members and bibliographical data [7–12].

A similar situation exists in relation to the remaining risk factors and their scoring [2–22]. The Polish Working Group members realise that the adopted scoring may be contested and may arouse minor controversies. At the same time, however, it is the simplest and the most rapid tool for a reliable and reproducible global assessment of thromboembolic risk. This has great practical implications. The scoring system may be used in clinical practice and in litigation. It is common knowledge that the question of using or, rather, failing to use thromboprophylaxis is increasingly the subject matter of various legal actions against doctors.

— 0–1 (małe ryzyko) — rekomenduje się wczesne uruchomienie chorego;

— 2 (umiarkowane ryzyko) — rekomenduje się stosowanie profilaktyki farmakologicznej zgodnie ze wskazaniem i zaleceniem producenta;

— 3 (duże ryzyko) — rekomenduje się stosowanie profilaktyki farmakologicznej zgodnie z zaleceniem producenta. W razie stwierdzenia przeciwwskazań do profilaktyki farmakologicznej zaleca się stosowanie profilaktyki metodami fizykalnymi;

— 4 i więcej (bardzo duże ryzyko) — rekomenduje się łączenie profilaktyki farmakologicznej i przerywanego pneumatycznego ucisku kończyn dolnych.

W każdym przypadku przed zastosowaniem profilaktyki przeciwzakrzepowej należy przeanalizować obecność ewentualnych przeciwwskazań. W przypadku przeciwwskazań do profilaktyki metodami farmakologicznymi zaleca się wykorzystanie metod fizykalnych [62, 66–73, 75–92, 193, 199, 204, 328–333, 361–365, 392, 401, 415, 487, 488, 491, 506–509, 512].

Rekomenduje się rozważenie przedłużenia pierwotnej profilaktyki przeciwzakrzepowej u wybranych pacjentów do 28 dni po wypisie ze szpitala z zastosowaniem heparyny drobnocząsteczkowej podawanej podskórnie 1 raz na dobę, u pacjentów po zabiegu operacyjnym z powodu nowotworu złośliwego lub zabiegu z zakresu chirurgii wysokiego ryzyka rozwoju żyłnej choroby zakrzepowo-zatorowej, o ile nie wiąże się to z niemożliwym do akceptacji wysokim ryzykiem powikłań krwotocznych [152, 170].

Za profilaktykę farmakologiczną uznaje się stosowanie heparyny niefrakcjonowanej [19–21, 45, 54, 74, 181–183, 191, 200, 201, 259–261, 389, 467, 489, 492–494, 558], heparyn drobnocząsteczkowych [23–42, 45, 54, 63–65, 74, 300–301, 304, 325, 344, 345–351, 366–371, 374–375, 382–384, 427, 431, 442, 448, 450–456, 458–463, 471, 474–476, 561–562, 565], pentasacharydów [91, 106, 292, 351–356, 423], doustnych bezpośrednich inhibitorów aktywnego czynnika X i czynnika II [573–583], zgodnie z zarejestrowanymi wskazaniami.

W profilaktyce żyłnej choroby zakrzepowo-zatorowej nie rekomenduje się stosowania kwasu acetylosalicylowego i innych leków przeciwplateletkowych [93–104, 194, 294].

## Omówienie wyników

Przyporządkowanie odpowiednich punktów czynnikom ryzyka czy sytuacjom klinicznym zawsze może budzić pewne kontrowersje [2–17]. Wynikają one na przykład z dość arbitralnego podziału zabiegów chirurgicznych ze względu na czas trwania. Wydaje się jednak,

Of the risk factors representing 1 point, central venous access and varicose are subject to the greatest controversy [3, 4, 45]. According to the current American College of Chest Physicians (ACCP) recommendations [45], the presence of a central venous catheter is not an indication for routine thromboprophylaxis. The Polish Working Group members have reached a consensus, however, that maintenance of catheters in central veins or the presence of varicose veins slightly increase thromboembolic risk, hence the inclusion of these risk factors in the one-point group. At the same time, the presence of any of the above factors as the only risk factor (yielding a total score of 1) does not constitute a recommendation for thromboprophylaxis, which is in line with the current ACCP recommendations.

None of the risk factors assigned 2 or 3 points arouse controversy.

Repeat surgery as a risk factor assigned 5 points may raise certain doubts. The Polish Working Group members, analysing their own clinical experience and the relatively scarce bibliography [1, 7, 10, 11], have concluded that repeat surgery is a very important factor that increases thromboembolic risk.

The risk factors applicable to women only do not arouse any significant controversy.

While analysing the Polish Working Group's recommendations, it should be emphasised that its members have considered it appropriate to use the recommended drugs in accordance with their approved labels and the manufacturer's recommendations, which are based on phase-III clinical trials. If any indication of a given drug is not approved, this means that no relevant trials have been conducted in this indication, and it is therefore difficult to predict the therapeutic efficacy of the drug in a given clinical setting. It should also be noted that off-label use of a drug or use of the drug against the manufacturer's recommendations may be harmful to the patient and therefore dangerous to the doctor. This applies both to the efficacy and the safety of a given product. It is therefore very important that the surgeon is familiar with the detailed characteristics of the drugs he or she uses.

The recommendation to combine pharmacological with physical methods of thromboprophylaxis in cases associated with the highest thromboembolic risk seems obvious and understandable [1, 19, 20]. It should be noted that the authors of this paper have concluded that combining physical with pharmacological methods increases the effectiveness of thromboprophylaxis.

The recommendations include novel anticoagulants: oral direct inhibitors of factor Xa and factor II [573–583]. In light of the phase III clinical trials, the use

że zastosowana metoda przyporządkowania odpowiedniej punktacji do czasu trwania zabiegu chirurgicznego jest zasadna i ma odzwierciedlenie w doświadczeniu klinicznym członków Polskiej Grupy Roboczej oraz w danych z piśmiennictwa [7–12].

Podobnie dzieje się także z pozostałymi czynnikami ryzyka i ich punktacją [2–22]. Członkowie Polskiej Grupy Roboczej zdają sobie sprawę, że przyjęta punktacja może być kontestowana i może być także źródłem niewielkich kontrowersji. Jednocześnie stanowi ona najprostsze i najszybsze w użyciu narzędzie rzetelnej i powtarzalnej globalnej oceny skali zagrożenia powikłaniami zakrzepowo-zatorowymi. Fakt ten ma duże znaczenie praktyczne. Skalę punktową można wykorzystać w praktyce klinicznej, a także w spornych przypadkach w celach prawnych. Wiadomo, że problematyka stosowania lub częściej niestosowania profilaktyki przeciwzakrzepowej coraz intensywniej pojawia się w różnego typu sprawach sądowych z udziałem lekarzy.

Z grupy czynników ryzyka, którym przyporządkowano 1 punkt, największe kontrowersje budzą cewnik w żyłę centralną i żyłki kończyn dolnych [3, 4, 45]. Według aktualnych zaleceń *American College of Chest Physicians* (ACCP) [45] obecność cewnika w żyłę centralną nie stanowi wskazania do rutynowego stosowania profilaktyki przeciwzakrzepowej. Członkowie Polskiej Grupy Roboczej na drodze konsensusu uznali jednak, że utrzymywanie cewników z żyłach centralnych lub obecność żyłaków kończyn dolnych zwiększają nieznacznie ryzyko rozwoju powikłań zakrzepowo-zatorowych, stąd przypisano ich obecności 1 punkt. Fakt wystąpienia któregoś z wymienionych czynników jako jedynego (globalna punktacja 1) nie stanowi jednocześnie według niniejszych rekomendacji wskazania do zastosowania profilaktyki przeciwzakrzepowej, co zgodne jest z aktualnymi zaleceniami ACCP.

Wśród wymienionych czynników ryzyka, którym przypisano 2 i 3 punkty, żaden nie budzi kontrowersji.

Reoperacja jako czynnik ryzyka, któremu przypisano 5 punktów, może budzić pewne wątpliwości. Członkowie Polskiej Grupy Roboczej, analizując własne doświadczenie kliniczne oraz stosunkowo skąpe dane z piśmiennictwa [1, 7, 10, 11], uznali reoperację za bardzo istotny czynnik zwiększający ryzyko wystąpienia powikłań zakrzepowo-zatorowych.

Czynniki ryzyka stwierdzane jedynie u kobiet nie budzą większych kontrowersji.

Analizując rekomendacje Polskiej Grupy Roboczej, warto podkreślić, że jej członkowie uznali za właściwe stosowanie leków zgodnie z rejestracją i zaleceniami producenta, które opierają się na przeprowadzonych badaniach klinicznych trzeciej fazy. Jeśli któryś z leków

of these products in line with the approved indications arouses no controversy. However, due to their price, the use of rivaroxaban or dabigatran in Poland is very limited.

It is obvious that despite the advent of effective novel anticoagulants (the considerable cost of which discourages doctors from prescribing them), LMWHs remain the principal agents used in thromboprophylaxis in surgery. It is therefore very important that the surgeon is familiar with their clinical characteristics. This information can be found, for instance, on [www.thrombosis.pl](http://www.thrombosis.pl).

Of note is the fact that the Polish Working Group experts recommend that prolongation of primary thromboprophylaxis be considered in selected patients until 28 days post-discharge with the use of once-daily subcutaneous LMWH, in patients following surgery for cancer or following a surgical procedure associated with a high risk of VTE, unless it is associated with an unacceptably high risk of haemorrhagic complications. This recommendation is based on the results of clinical trials in oncological and general surgery.

Again, it is noteworthy that the Polish Working Group members do not recommend the use of acetylsalicylic acid or other antiplatelet drugs in the prevention of VTE.

The Polish Working Group experts hope that the presented scoring system will be a simple tool that will be commonly used in clinical practice by Polish practitioners. In order to simplify and facilitate the use of the scoring system, the development of an electronic version, including one for mobile phones, has been planned. The authors hope that this electronic application for the scoring system will reduce the number of mistakes and errors, which unfortunately are so common in Polish hospitals [43, 44].

The members of the Polish Working Group would like to emphasise that the proposed update of the scoring system originally developed by Joseph Caprini has not been verified in clinical practice, so it should only serve as a guide rather than being obligatory for practitioners in the assessment of VTE risk.

### Members of the Polish Working Group

**Chair:** Prof. Witold Tomkowski

**Secretary:** Dr Paweł Kuca

**Members (in alphabetical order):** Prof. Piotr Andziak, Prof. Adam Dziki, Prof. Rafał Niżankowski, Prof. Walerian Staszkiwicz, Doc. Jerzy Windyga, Prof. Jacek Wroński

**Corresponding members (in alphabetical order):** Prof. Janusz Andres, Prof. Jacek Imiela, Prof. Arkadiusz Jawień, Prof. Jan Kulig, Doc. Tomasz Urbanek

nie jest zarejestrowany w danym wskazaniu, oznacza to, że nie wykonano odnośnych badań klinicznych dotyczących tego wskazania i trudno przewidzieć, jaka będzie skuteczność terapeutyczna danego leku w konkretnej sytuacji klinicznej. Warto podkreślić, że zastosowanie danego preparatu niezgodnie z rejestracją czy zaleceniami producenta może być groźne dla pacjenta, a tym samym dla lekarza. Dotyczy to zarówno skuteczności, jak i bezpieczeństwa danego preparatu. Dlatego tak ważna jest znajomość szczegółowej charakterystyki poszczególnych leków wchodzących w skład armamentarium chirurga.

Wydaje się oczywiste i zrozumiałe rekomendowanie łączenia metod farmakologicznych i fizykalnych profilaktyki przeciwzakrzepowej w przypadkach największego zagrożenia powikłaniami zakrzepowo-zatorowymi [1, 19, 20]. Warto podkreślić, że autorzy artykułu uznali, że takie postępowanie zwiększa efektywność profilaktyki przeciwzakrzepowej.

W rekomendacjach pojawiają się nowe leki przeciwzakrzepowe: doustne bezpośrednie inhibitory aktywnego czynnika X i czynnika II [573–583]. W świetle przeprowadzonych badań klinicznych trzeciej fazy stosowanie wymienionych preparatów zgodnie z zarejestrowanymi wskazaniami nie budzi kontrowersji. Jednak ze względu na cenę szerokie zastosowanie kliniczne rywaroksabanu czy dabigatranu w Polsce jest bardzo ograniczone.

Jest oczywiste, że obecnie pomimo pojawienia się efektywnych, nowych leków przeciwzakrzepowych (zbyt wysoka cena zniechęca do ich zalecania) podstawowymi preparatami stosowanymi w profilaktyce przeciwzakrzepowej w dyscyplinach zabiegowych pozostają w Polsce heparyny drobnocząsteczkowe. Dlatego tak ważna jest dla lekarza praktyka znajomość ich charakterystyki klinicznej. Można ją znaleźć między innymi na stronach internetowych [www.thrombosis.pl](http://www.thrombosis.pl).

Warto podkreślić, że eksperci Polskiej Grupy Roboczej rekomendują rozważenie przedłużenia do 28 dni pierwotnej profilaktyki przeciwzakrzepowej u wybranych pacjentów po wypisie ze szpitala z zastosowaniem heparyny drobnocząsteczkowej podawanej podskórnie raz na dobę, u pacjentów po zabiegu operacyjnym z powodu nowotworu złośliwego lub zabiegu z zakresu chirurgii wysokiego ryzyka rozwoju żylnych chorób zakrzepowo-zatorowych, o ile nie wiąże się to z niemożliwym do zaakceptowania wysokim ryzykiem powikłań krwotocznych. Rekomendacja ta opiera się na wynikach badań klinicznych z zakresu chirurgii onkologicznej oraz chirurgii ogólnej.

Warto ponownie podkreślić, że członkowie Polskiej Grupy Roboczej w profilaktyce żylnych chorób

## References

1. Caprini JA, Arcelus JI, Hasty JH et al (1991) Clinical assessment of venous thromboembolic risk in surgical patients. *Semin Thromb Haemost*, 17 (suppl 3): 304–312.
2. National Institute for Health and Clinical Excellence (2008) Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. NICE clinical guideline No. 46:1–160. Available at: <http://www.nice.org.uk/CG046>. Accessed March 31.
3. Anderson FA, Wheeler HB, Goldberg RJ et al (1992) The prevalence of risk factors for venous thromboembolism among hospital patients. *Arch Intern Med*, 152:1660–1664.
4. Rosendaal FR (1999) Risk factors for venous thrombotic disease. *Thromb Haemost*, 82: 610–619.
5. Rosendaal FR (1999) Venous thrombosis: a multicausal disease. *Lancet*, 353: 1167–1173.
6. Heit JA, O'Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. *Arch Intern Med*, 162: 1245–1248.
7. Anderson FA, Spencer FA (2003) Risk factors for venous thromboembolism. *Circulation*, 107: 19–116.
8. Samama MM, Dahl OE, Quinlan DJ et al (2003) Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. *Haematologica*, 88: 1410–1421.
9. Edmonds MJ, Crichton TJ, Runciman WB (2004) Evidence-based risk factors for postoperative deep vein thrombosis. *ANZ J Surg*, 74: 1082–1097.
10. Kucher N, Tapson VF, Goldhaber SZ, for the DVT FREE Steering Committee (2005) Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. *Thromb Haemost*, 93: 494–498.
11. Gangireddy C, Rectenwald JR, Upchurch GR et al (2007) Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. *J Vasc Surg*, 45: 335–342.
12. Zhan C, Miller MR (2003) Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. *JAMA*, 290: 1868–1874.
13. Kearon C (2003) Natural history of venous thromboembolism. *Circulation*, 107 (23 suppl 1): 122–130.
14. White RH, Zhou H, Romano PS (2003) Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. *Thromb Haemost*, 90: 446–455.
15. Shojania KG, Duncan BW, McDonald KM et al (2008) Making health care safer: a critical analysis of patient safety practices; evidence report/technology assessment No. 43 (prepared by the University of California at San Francisco-Stanford Evidence-Based Practice Center under contract No. 290–97-0013). AHRQ Publication No. 01-E058, Rockville, MD. Agency for Healthcare Research and Quality. Available at: [www.ahrq.gov/clinic/ptsafety/](http://www.ahrq.gov/clinic/ptsafety/). Accessed March 31, 2008.
16. Sullivan SD, Kahn SR, Davidson BL et al (2003) Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. *Pharmacoeconomics*, 21: 477–496.
17. Caprini JA, Botteman MF, Stephens JM et al (2003) Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. *Value Health*, 6: 59–74.
18. Avorn J, Winkelmayer WC (2004) Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism. *Circulation*, 110 (suppl IV): IV25–IV32.
19. Collins R, Scrimgeour A, Yusuf S (1988) Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. *N Engl J Med*, 318: 1162–1173.
20. Clagett GP, Reisch JS (1988) Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. *Ann Surg*, 208: 227–240.
21. Nurmohamed MT, Rosendaal FR, Buller HR et al (1992) Lowmolecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. *Lancet*, 340: 152–156.

zakrzepowo-zatorowej nie rekomendują stosowania kwasu acetylosalicylowego i innych leków przeciwplatektykowych.

Eksperti Polskiej Grupy Roboczej mają nadzieję, że prezentowana skala punktowa będzie stanowić proste narzędzie stosowane powszechnie w praktyce klinicznej przez polskich lekarzy praktyków. Aby ułatwić i uprościć używanie skali, zaplanowano przygotowanie jej w wersji elektronicznej, możliwej do wykorzystania nawet w telefonach komórkowych. Autorzy mają nadzieję, że tego typu elektroniczna aplikacja skali punktowej zmniejszy liczbę pomyłek i błędów — niestety tak powszechnych w polskich szpitalach [43, 44].

Członkowie Polskiej Grupy Roboczej pragną podkreślić, że proponowanej aktualizacji skali punktowej Josepha Capriniego dotychczas nie sprawdzano w praktyce klinicznej, a zatem stanowi jedynie formę pomocy, a nie zalecenia czy obowiązku stosowania przez lekarzy praktyków w ocenie ryzyka rozwoju żylnych chorób zakrzepowo-zatorowych.

## Skład Polskiej Grupy Roboczej

**Przewodniczący:** Prof. Witold Tomkowski

**Sekretarz:** Dr Paweł Kuca

**Członkowie (w kolejności alfabetycznej):** Prof. Piotr Andziak, Prof. Adam Dziki, Prof. Rafał Niżankowski, Prof. Walerian Staszkiwicz, Doc. Jerzy Windyga, Prof. Jacek Wroński

**Członkowie korespondencyjni (w kolejności alfabetycznej):** Prof. Janusz Andres, Prof. Jacek Imiela, Prof. Arkadiusz Jawień, Prof. Jan Kulig, Doc. Tomasz Urbanek



22. Kakkar VV, Cohen AT, Edmonson RA et al (1993) Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. *Lancet*, 341: 259–265.
23. Jorgensen LN, Wille-Jorgensen P, Hauch O (1993) Prophylaxis of postoperative thromboembolism with low molecular weight heparins. *Br J Surg*, 80: 689–704.
24. Thomas DP (1997) Does low molecular weight heparin cause less bleeding? *Thromb Haemost*, 78: 1422–1425.
25. Koch A, Ziegler S, Breitschwerdt H et al (2001) Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. *Thromb Res*, 102: 295–309.
26. Haas S, Wolf H, Kakkar AK et al (2005) Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. *Thromb Haemost*, 94: 814–819.
27. Nicolaides AN, Fareed J, Kakkar AK et al (2006) Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). *Int Angiol*, 25: 101–161.
28. Ahmad HA, Geissler A, MacLellan DG (2002) Deep venous thrombosis prophylaxis: are guidelines being followed? *ANZ J Surg*, 72: 331–334.
29. Kakkar AK, Levine M, Pinedo HM et al (2003) Venous thrombosis in cancer patients: insights from the FRONT-LINE survey. *Oncologist*, 8: 381–388.
30. Ellis MH, Elis A (2004) Perioperative venous thromboembolism prophylaxis in Israel: a survey of academic surgical departments. *Eur J Haematol*, 73: 104–108.
31. National Institute of Clinical Studies (2005) The prevalence of chemoprophylaxis in surgical and medical cases at high risk of venous thromboembolism. Melbourne, Australia: School of Population Health, University of Western Australia, 1–27.
32. Rashid ST, Thursz MR, Razvi NA et al (2005) Venous thromboprophylaxis in UK medical inpatients. *J R Soc Med*, 98: 507–512.
33. Stinnett JM, Pendleton R, Skordos L et al (2005) Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates. *Am J Hematol*, 78: 167–172.
34. Tapson VF, Hyers TM, Waldo AL et al (2005) Antithrombotic therapy practices in US hospitals in an era of practice guidelines. *Arch Intern Med*, 165: 1458–1464.
35. Deheinzelin D, Braga AL, Martins LC et al (2006) Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil. *J Thromb Haemost*, 4: 1266–1270.
36. Rajaganeshan R, Dussa CU, Sahni V (2006) National survey in the United Kingdom of prophylaxis of deep vein thrombosis for patients with fracture of the neck of the femur. *Injury*, 37: 721–726.
37. Kahn SR, Panju A, Geerts W et al (2007) Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. *Thromb Res*, 119: 145–155.
38. Yu HT, Dylan ML, Lin J et al (2007) Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. *Am J Health Syst Pharm*, 64: 69–76.
39. Schunemann HJ, Cook D, Grimshaw J et al (2004) Antithrombotic and thrombolytic therapy: from evidence to application: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, 126: 688S–696S.
40. Tooher R, Middleton P, Pham C et al (2005) A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. *Ann Surg*, 241: 397–415.
41. McMullin J, Cook D, Griffith L et al (2006) Minimizing errors of omission: Behavioural Reinforcement of Heparin To Avert Venous Emboli: the BEHAVE Study. *Crit Care Med*, 34: 694–699.
42. Timmons S, O'Callaghan C, O'Connor M et al (2005) Audit-guided action can improve the compliance with thromboembolic prophylaxis prescribing to hospitalized, acutely ill older adults. *J Thromb Haemost*, 3: 2112–2113.
43. Mosen D, Elliott CG, Egger MJ et al (2004) The effect of a computerized reminder system on the prevention of postoperative venous thromboembolism. *Chest*, 125: 1635–1641.
44. Kucher N, Koo S, Quiroz R et al (2005) Electronic alerts to prevent venous thromboembolism among hospitalized patients. *N Engl J Med*, 352: 969–977.
45. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8<sup>th</sup> Edition). *Chest*, 133: 381–453.
46. Greenfield LJ, Proctor MC, Rodriguez JL et al (1997) Posttrauma thromboembolism prophylaxis. *J Trauma*, 42: 100–103.
47. Samama MM (1999) Applying risk assessment models in general surgery: effective risk stratification. *Blood Coagul Fibrinolysis*, 10 (suppl 2): S79–S84.
48. Cohen AT, Alikhan R, Arcelus JI et al (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. *Thromb Haemost*, 94: 750–759.
49. Chopard P, Spirk D, Bounameaux H (2006) Identifying acutely ill medical patients requiring thromboprophylaxis. *J Thromb Haemost*, 4: 915–916.
50. Samama MM, Dahl OE, Mismetti P et al (2006) An electronic tool for venous thromboembolism prevention in medical and surgical patients. *Haematologica*, 91: 64–70.
51. Lassen MR, Borris LC, Bäck S et al (1999) Clinical limitations of risk assessment models. *Blood Coagul Fibrinolysis*, 10 (suppl 2): S45–S51.
52. Tomkowiak WZ, Davidson BL, Wisniewska J et al (2007) Accuracy of compression ultrasound in screening for deep venous thrombosis in acutely ill medical patients. *Thromb Haemost*, 97: 191–194.
53. Schellong SM, Beyer J, Kakkar AK et al (2007) Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. *J Thromb Haemost*, 7: 1431–1437.
54. Leizorovicz A, Kassai B, Becker F et al (2003) The assessment of deep vein thromboses for therapeutic trials. *Angiology*, 54: 19–24.
55. Kassai B, Boissel JP, Cucherat M et al (2004) A systematic review of the accuracy of ultrasound in the diagnosis of deep venous thrombosis in asymptomatic patients. *Thromb Haemost*, 91: 655–666.

56. Lee AY, Gent M, Julian JA et al (2004) Bilateral vs. Ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. *J Thromb Haemost*, 2: 1752–1759.
57. Lagor C, Elliott CG, Stoddard GJ et al (2005) Weaknesses in the classification criteria for antithrombotic-related major bleeding events. *Thromb Haemost*, 94: 997–1003.
58. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost*, 3: 692–694.
59. Segers AE, Prins MH, Lensing AW et al (2005) Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies? *J Thromb Haemost*, 3: 1099–1102.
60. O'Donnell M, Kearon C (2007) Thromboembolism prevention in ischaemic stroke. *Lancet*, 369: 1413–1415.
61. Quinlan DJ, Eikelboom JW, Dahl OE et al (2007) Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. *J Thromb Haemost*, 5: 1438–1443.
62. Agu O, Hamilton G, Baker D (1999) Graduated compression stockings in the prevention of venous thromboembolism. *Br J Surg*, 86: 992–1004.
63. Freedman KB, Brookenthal KR, Fitzgerald RH et al (2000) A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. *J Bone Joint Surg Am*, 82: 929–938.
64. Westrich GH, Haas SB, Mosca P et al (2000) Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. *J Bone Joint Surg Br*, 82: 795–800.
65. Handoll HH, Farrar MJ, McBirnie J et al (2002) Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. *Cochrane Database Syst Rev*, 4: CD000305.
66. Lachiewicz PF, Kelley SS, Haden LR (2004) Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty: a prospective, randomised study. *J Bone Joint Surg Br*, 86: 1137–1141.
67. Silbersack Y, Taute BM, Hein W et al (2004) Prevention of deep-vein thrombosis after total hip and knee replacement: low-molecular-weight heparin in combination with intermittent pneumatic compression. *J Bone Joint Surg Br*, 86: 809–812.
68. Roderick P, Ferris G, Wilson K et al (2005) Towards evidencebased guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technol Assess*, 9: 1–78.
69. Urbankova J, Quiroz R, Kucher Net al (2005) Intermittent pneumatic compression and deep vein thrombosis prevention: a meta-analysis in postoperative patients. *Thromb Haemost*, 94: 1181–1185.
70. Amaragiri SV, Lees TA (2000) Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev*, 1: CD001484.
71. Hull RD, Raskob GE, Gent M et al (1990) Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. *JAMA*, 263: 2313–2317.
72. Francis CW, Pellegrini VD, Marder VJ et al (1992) Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. *JAMA*, 267: 2911–2915.
73. Blanchard J, Meuwly JY, Leyvraz PF et al (1999) Prevention of deep-vein thrombosis after total knee replacement: randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. *J Bone Joint Surg Br*, 81: 654–659.
74. Iorio A, Agnelli G (2000) Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Arch Intern Med*, 160: 2327–2332.
75. Mazzone C, Chiodo Grandi F, Sandercock P et al (2004) Physical methods for preventing deep vein thrombosis in stroke. *Cochrane Database Syst Rev*, 4: CD001922.
76. Schulz SL, Stechemesser B, Seeberger U et al (2005) Graduated compression stockings for the prevention of venous thromboembolism in surgical patients in the age of low molecular weight heparins. *J Thromb Haemost*, 3: 2363–2365.
77. Coe NP, Collins RE, Klein LA et al (1978) Prevention of deep vein thrombosis in urological patients: a controlled, randomized trial of low-dose heparin and external pneumatic compression boots. *Surgery*, 83: 230–234.
78. Gallus A, Raman K, Darby T (1983) Venous thrombosis after elective hip replacement—the influence of preventive intermittent calf compression and of surgical technique. *Br J Surg*, 70: 17–19.
79. Westrich GH, Specht LM, Sharrock NE et al (2000) Pneumatic compression hemodynamics in total hip arthroplasty. *Clin Orthop*, 372: 180–191.
80. Morris RJ, Woodcock JP (2004) Evidence-based compression: prevention of stasis and deep vein thrombosis. *Ann Surg*, 239: 162–171.
81. Comerota AJ, Katz ML, White JV (1992) Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? *Am J Surg*, 164: 265–268.
82. Haddad FS, Kerry RM, McEwen JA et al (2001) Unanticipated variations between expected and delivered pneumatic compression therapy after elective hip surgery: a possible source of variation in reported patient outcomes. *J Arthroplasty*, 16: 37–46.
83. Cornwell EE, Chang D, Velmahos G et al (2002) Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. *Am Surg*, 68: 470–473.
84. Charalambous C, Cleanthous S, Tryfonidis M et al (2003) Foot pump prophylaxis for deep venous thrombosis—rate of effective usage following knee and hip arthroplasty. *Int Orthop*, 27: 208–210.
85. Turpie AG, Hirsh J, Gent M et al (1989) Prevention of deep vein thrombosis in potential neurosurgical patients: a randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. *Arch Intern Med*, 149: 679–681.
86. Lacut K, Bressollette L, Le Gal G et al (2005) Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. *Neurology*, 65: 865–869.

87. Wille-Jorgensen P (1996) Prophylaxis of postoperative thromboembolism with a combination of heparin and graduated compression stockings. *Int Angiol*, 15 (suppl 1): 15–20.
88. Kalodiki EP, Hoppensteadt DA, Nicolaidis AN et al (1996) Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement: a randomised controlled trial. *Int Angiol*, 15: 162–168.
89. Ramos R, Salem BI, De Pawlikowski MP et al (1996) The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. *Chest*, 109: 82–85.
90. Wille-Jorgensen P, Rasmussen MS, Andersen BR et al (2004) Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. *Cochrane Database Syst Rev*, 1: CD001217.
91. Turpie AG, Bauer KA, Caprini JA et al (2007) Fondaparinux combined with intermittent pneumatic compression versus intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. *J Thromb Haemost*, 5: 1854–1861.
92. Best AJ, Williams S, Crozier A et al (2000) Graded compression stockings in elective orthopaedic surgery: an assessment of the *in vivo* performance of commercially available stockings in patients having hip and knee arthroplasty. *J Bone Joint Surg Br*, 82: 116–118.
93. Patrono C, Collier B, FitzGerald GA et al (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*, 126 (suppl): 234S–264S.
94. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *BMJ*, 308: 235–246.
95. Lotke PA, Palevsky H, Keenan AM et al (1996) Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. *Clin Orthop*, 324: 251–258.
96. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) Trial. *Lancet*, 355: 1295–1302.
97. Scottish Intercollegiate Guidelines Network (SIGN) (2002) Prophylaxis of venous thromboembolism: a national clinical guideline; publication No. 62. Available at: <http://www.sign.ac.uk>. Accessed March 31, 2008.
98. Hovens MM, Snoep JD, Tamsma JT et al (2006) Aspirin in the prevention and treatment of venous thromboembolism. *J Thromb Haemost*, 4: 1470–1475.
99. Cohen AT, Skinner JA, Kakkar VV (1994) Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? *BMJ*, 309: 1213–1215.
100. McKenna R, Galante J, Bachmann F et al (1980) Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. *BMJ*, 280: 514–517.
101. Powers PJ, Gent M, Jay RM et al (1989) A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. *Arch Intern Med*, 149: 771–774.
102. Westrich GH, Sculco TP (1996) Prophylaxis against deep venous thrombosis after total knee arthroplasty: pneumatic planter compression and aspirin compared with aspirin alone. *J Bone Joint Surg Am*, 78: 826–834.
103. Graor RA, Stewart JH, Lotke PA et al (1992) RD heparin (ardeparin sodium) vs aspirin to prevent deep venous thrombosis after hip or knee replacement surgery [abstract]. *Chest*, 102: 118S.
104. Gent M, Hirsh J, Ginsberg JS et al (1996) Low-molecular-weight heparinoid orgran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. *Circulation*, 93: 80–84.
105. Cestac P, Bagheri H, Lapeyre-Mestre M et al (2003) Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. *Drug Safety*, 26: 197–207.
106. Turpie A, Bauer K, Eriksson B et al (2003) Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. *Thromb Haemost*, 90: 364–366.
107. Lim W, Dentali F, Eikelboom JW et al (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. *Ann Intern Med*, 144: 673–684.
108. Nagge J, Crowther M, Hirsh J (2002) Is impaired renal function a contraindication to the use of low-molecular-weight heparin? *Arch Intern Med*, 162: 2605–2609.
109. Grand'Maison A, Charest AF, Geerts WH (2005) Anticoagulant use in patients with chronic renal impairment. *Am J Cardiovasc Drugs*, 5: 291–305.
110. Mahe'I, Aghassarian M, Drouet L et al (2007) Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. *Thromb Haemost*, 97: 581–586.
111. Douketis J, Cook D, Zytaruk N et al (2007) Dalteparin thromboprophylaxis in critically ill patients with severe renal insufficiency: the DIRECT study [abstract]. *J Thromb Haemost*, 5 (suppl 2): P5–680.
112. Rodgers A, Walker N, Schug S et al (2000) Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ*, 321: 1493–1497.
113. Beattie WS, Badner NH, Choi P (2001) Epidural analgesia reduces postoperative myocardial infarction: a meta-analysis. *Anesth Analg*, 93: 853–858.
114. Wu CL, Hurley RV, Anderson GF et al (2004) Effect of postoperative epidural analgesia on morbidity and mortality following surgery in Medicare patients. *Reg Anesth Pain Med*, 29: 525–533.
115. Pellegrini VD, Donaldson CT, Farber DC et al (2005) Prevention of readmission for venous thromboembolic disease after total hip arthroplasty. *Clin Orthop*, 441: 56–62.
116. Guay J. The benefits of adding epidural analgesia to general anesthesia: a metaanalysis. *J Anesth*, 20: 335–340.
117. Nishimori M, Ballantyne JC, Low JH (2006) Epidural pain relief versus systemic opioid-based pain relief for abdominal aortic surgery. *Cochrane Database Syst Rev*, 3: CD005059.

118. Wu CL, Naqibuddin M, Fleisher LA (2001) Measurement of patient satisfaction as an outcome of regional anesthesia and analgesia: a systematic review. *Reg Anesth Pain Med*, 26: 196–208.
119. Block BM, Liu SS, Rowlingson AJ et al (2003) Efficacy of postoperative epidural analgesia: a meta-analysis. *JAMA*, 290: 2455–2463.
120. Choi PT, Bhandari M, Scott J et al (2003) Epidural analgesia for pain relief following hip or knee replacement. *Cochrane Database Syst Rev*, 3: CD003071.
121. Liu SS, Block BM, Wu CL (2004) Effects of perioperative central neuraxial analgesia on outcome after coronary artery bypass surgery: a meta-analysis. *Anesthesiology*, 101: 153–161.
122. Wu CL, Cohen SR, Richman JM et al (2005) Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: a meta-analysis. *Anesthesiology*, 103: 1079–1088.
123. Horlocker TT, Wedel DJ, Benzon H et al (2003) Regional anesthesia in the anticoagulated patient: defining the risks (the Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). *Reg Anesth Pain Med*, 28: 172–197.
124. Moen V, Dahlgren N, Irestedt L (2004) Severe neurological complications after central neuraxial blockades in Sweden 1990–1999. *Anesthesiology*, 101: 950–959.
125. Vandermeulen EP, Van Aken H, Vermeylen J (1994) Anticoagulants and spinal-epidural anesthesia. *Anesth Analg*, 79: 1165–1177.
126. Rowlingson JC, Hanson PB (2005) Neuraxial anesthesia and lowmolecular-weight heparin prophylaxis in major orthopedic surgery in the wake of the latest American Society of Regional Anesthesia guidelines. *Anesth Analg*, 100: 1482–1488.
127. Douketis J, Wang J, Cuddy K et al (2006) The safety of coadministered continuous epidural analgesia and low-molecularweight heparin after major orthopedic surgery: assessment of a standardized patient management protocol. *Thromb Haemost*, 96: 387–389.
128. Douketis JD, Dentali F (2006) Managing anticoagulant and antiplatelet drugs in patients who are receiving neuraxial anesthesia and epidural analgesia: a practical guide for clinicians. *Tech Reg Anesth Pain Manage*, 10: 46–55.
129. Parvizi J, Viscusi ER, Frank HG et al (2007) Can epidural anesthesia and warfarin be coadministered? *Clin Orthop*, 456: 133–137.
130. Chelly JE, Greger J, Gebhard R et al (2001) Continuous femoral blocks improve recovery and outcome of patients undergoing total knee arthroplasty. *J Arthroplasty*, 16: 436–445.
131. Davies RG, Myles PS, Graham JM (2006) A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy: a systematic review and meta-analysis of randomized trials. *Br J Anaesth*, 96: 418–426.
132. Richman JM, Liu SS, Courpas G et al (2006) Does continuous peripheral nerve block provide superior pain control to opioids? A meta-analysis. *Anesth Analg*, 102: 248–257.
133. Capdevila X, Pirat P, Bringuier S et al (2005) Continuous peripheral nerve blocks in hospital wards after orthopedic surgery: a multicenter prospective analysis of the quality of postoperative analgesia and complications in 1,416 patients. *Anesthesiology*, 103: 1035–1045.
134. Mismetti P, Laporte S, Darmon JY et al (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. *Br J Surg* 2001; 88: 913–930.
135. Nicolaides A, Irving D, Pretzell M et al (1973) The risk of deep-vein thrombosis in surgical patients [abstract]. *Br J Surg*, 60: 312.
136. Wille-Jorgensen P, Ott P (1990) Predicting failure of low-dose prophylactic heparin in general surgical procedures. *Surg Gynecol Obstet*, 171: 126–130.
137. Flordal PA, Bergqvist D, Burmark US et al (1996) Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. *Eur J Surg*, 162: 783–789.
138. Agnelli G, Bolis G, Capussotti L et al (2006) A clinical outcomebased prospective study on venous thromboembolism after cancer surgery: the ARISTOS project. *Ann Surg*, 243: 89–95.
139. Enoch S, Woon E, Blair SD (2003) Thromboprophylaxis can be omitted in selected patients undergoing varicose vein surgery and hernia repair. *Br J Surg*, 90: 818–820.
140. Riber C, Alstrup N, Nymann Tet al (1996) Postoperative thromboembolism after day-case herniorrhaphy. *Br J Surg*, 83: 420–421.
141. Hendolin H, Mattila MA, Poikolainen E (1981) The effect of lumbar epidural analgesia on the development of deep vein thrombosis of the legs after open prostatectomy. *Acta Chir Scand*, 147: 425–429.
142. Prins MH, Hirsh J (1990) A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review. *Thromb Haemost*, 64: 497–500.
143. Second Thromboembolic Risk Factors (THRIFT II) Consensus Group (1998) Risk of and prophylaxis for venous thromboembolism in hospital patients. *Phlebology*, 13: 87–97.
144. Bergqvist D (2004) Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. *Br J Surg*, 91: 965–974.
145. Leizorovicz A, Haugh MC, Chapuis FR et al (1992) Low molecular weight heparin in prevention of perioperative thrombosis. *BMJ*, 305: 913–920.
146. Koch A, Bouges S, Ziegler S et al (1997) Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. *Br J Surg*, 84: 750–759.
147. Palmer AJ, Schramm W, Kirchhof B et al (1997) Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. *Haemostasis*, 27: 65–74.
148. Breddin HK (1999) Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery. *Semin Thromb Haemost*, 25 (suppl 3): 83–89.
149. Wicky J, Couson F, Ambrosetti P et al (1993) Postoperative deep venous thrombosis (DVT) and low-molecular weight heparin (LMWH) type and dosage. *Thromb Haemost*, 69: 402–403.
150. Bergqvist D, Burmark US, Flordal PA et al (1995) Low molecular weight heparin started before surgery as pro-

- phylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. *Br J Surg*, 82: 496–501.
151. Wiig JN, Solhaug JH, Bilberg T et al (1995) Prophylaxis of venographically diagnosed deep vein thrombosis in gastrointestinal surgery: multicentre trials 20 mg and 40 mg enoxaparin versus dextran. *Eur J Surg*, 161: 663–668.
  152. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. *Br J Surg*, 84: 1099–1103.
  153. Simonneau G, Laporte S, Mismetti P et al (2006) A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. *J Thromb Haemost*, 4: 1693–1700.
  154. Nurmohamed MT, Verhaeghe R, Haas S et al (1995) A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. *Am J Surg*, 169: 567–571.
  155. Kakkar VV, Boeckl O, Boneu B et al (1997) Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: european multicenter trial. *World J Surg*, 21: 2–9.
  156. Bergqvist D, Burmark US, Frisell J et al (1986) Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily: a prospective double-blind multicentre trial on prevention of postoperative thrombosis. *Br J Surg*, 73: 204–208.
  157. Bergqvist D, Matzsch T, Burmark US et al (1988) Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. *Br J Surg*, 75: 888–891.
  158. McLeod RS, Geerts WH, Sniderman KW et al (2001) Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. *Ann Surg*, 233: 438–444.
  159. International Multicentre Trial (1975) Prevention of fatal postoperative pulmonary embolism by low doses of heparin. *Lancet*, 2: 45–51.
  160. Sagar S, Massey J, Sanderson JM (1975) Low-dose heparin prophylaxis against fatal pulmonary embolism. *BMJ*, 4: 257–259.
  161. Pezzuoli G, Neri Serneri GG, Settembrini P et al (1989) Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular-weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). *Int Surg*, 74: 205–210.
  162. Wolf H, Encke A, Haas S et al (1991) Comparison of the efficacy and safety of Sandoz low molecular weight heparin and unfractionated heparin: interim analysis of a multicenter trial. *Semin Thromb Haemost*, 17: 343–346.
  163. Agnelli G, Bergqvist D, Cohen AT et al (2005) Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. *Br J Surg*, 92: 1212–1220.
  164. Scurr JH, Coleridge-Smith PD, Hasty JH (1987) Regimen for improved effectiveness of intermittent pneumatic compression in deep venous thrombosis prophylaxis. *Surgery*, 102: 816–820.
  165. Lindblad B, Eriksson A, Bergqvist D (1991) Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1968. *Br J Surg*, 78: 849–852.
  166. Huber O, Bounameaux H, Borst F et al (1992) Post-operative pulmonary embolism after hospital discharge: an underestimated risk. *Arch Surg*, 127: 310–313.
  167. Lausen I, Jensen R, Jorgensen LN et al (1998) Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. *Eur J Surg*, 164: 657–663.
  168. Heit JA, Silverstein MD, Mohr DN et al (2001) The epidemiology of venous thromboembolism in the community. *Throm Haemost*, 86: 452–463.
  169. Bergqvist D, Agnelli G, Cohen AT et al (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. *N Engl J Med*, 346: 975–980.
  170. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P et al (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. *J Thromb Haemost*, 4: 2384–2390.
  171. Warkentin TE, Levine MN, Hirsh J et al (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med*, 332: 1330–1335.
  172. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood*, 106: 2710–2715.
  173. Collins TC, Soucek J, Beyth RJ (2004) Benefits of anti-thrombotic therapy after infrainguinal bypass grafting: a meta-analysis. *Am J Med*, 117: 93–99.
  174. Jackson MR, Johnson WC, Williford WO et al (2002) The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial. *J VascSurg*, 35: 292–298.
  175. Olin JW, Graor RA, O'Hara P et al (1993) The incidence of deep venous thrombosis in patients undergoing abdominal aortic aneurysm resection. *J Vasc Surg*, 18: 1037–1041.
  176. Fletcher JP, Batiste P. Incidence of deep vein thrombosis following vascular surgery. *Int Angiol*, 16: 65–68.
  177. Farkas JC, Chapuis C, Combe S et al (1993) A randomised controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing vascular surgery. *Eur J Vasc Surg*, 7: 554–560.
  178. Hollyoak M, Woodruff P, Muller M et al (2001) Deep venous thrombosis in postoperative vascular surgical patients: a frequent finding without prophylaxis. *J Vasc Surg*, 34: 656–660.
  179. Prandoni P, Bilora F, Marchiori A et al (2003) An association between atherosclerosis and venous thrombosis. *N Engl J Med*, 348: 1435–1441.
  180. Eliasson A, Bergqvist D, Bjorck M et al (2006) Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based

- on 23,796 consecutive autopsies. *J Thromb Haemost*, 4: 1897–1902.
181. Belch JJ, Lowe GD, Pollock JG et al (1979) Low dose heparin in the prevention of deep-vein thrombosis after aortic bifurcation graft surgery. *Thromb Haemost*, 42: 1429–1433.
  182. Spebar MJ, Collins GJ, Rich NM et al (1981) Perioperative heparin prophylaxis of deep venous thrombosis in patients with peripheral vascular disease. *Am J Surg*, 142: 649–650.
  183. Killewich LA, Aswad MA, Sandager GP et al (1997) A randomized, prospective trial of deep venous thrombosis prophylaxis in aortic surgery. *Arch Surg*, 132: 499–504.
  184. Abu-Rustum NR, Richard S, Wilton A et al (2005) Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. *Gynecol Oncol*, 99: 320–326.
  185. Clarke-Pearson DL, Dodge RK, Synan I et al (2003) Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. *Obstet Gynecol*, 101: 157–163.
  186. Jacobson GM, Kamath RS, Smith BJ et al (2005) Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. *Gynecol Oncol*, 96: 470–474.
  187. Tateo S, Mereu L, Salamano S et al (2005) Ovarian cancer and venous thromboembolic risk. *Gynecol Oncol*, 99: 119–125.
  188. Martino MA, Borges E, Williamson E et al (2006) Pulmonary embolism after major abdominal surgery in gynecologic oncology. *Obstet Gynecol*, 107: 666–671.
  189. Wang X, Fu S, Freedman RS et al (2006) Venous thromboembolism syndrome in gynecological cancer. *Int J Gynecol Cancer*, 16 (suppl 1): 458–471.
  190. Heilmann L, von Tempelhoff GF, Schneider D (1998) Prevention of thrombosis in gynecologic malignancy. *Clin Appl Thromb/Hemost*, 4: 153–159.
  191. Ward B, Pradhan S (1998) Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. *Aust NZ J Obstet Gynaecol*, 38: 91–92.
  192. Baykal C, Al A, Demirtas E et al (2001) Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. *Eur J Gynaec Oncol*, 22: 127–130.
  193. Maxwell GL, Synan I, Dodge R et al (2001) Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. *Obstet Gynecol*, 98: 989–995.
  194. Oates-Whitehead RM, D'Angelo A, Mol B (2003) Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. *Cochrane Database Syst Rev* 2003; 4: CD003679.
  195. Ageno W, Manfredi E, Dentali F et al (2007) The incidence of venous thromboembolism following gynecologic laparoscopy: a multicenter, prospective cohort study. *J Thromb*, 103: 271–276.
  196. Abu-Rustum NR, Chi DS, Sonoda Y et al (2003) Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. *Gynecol Oncol*, 89: 504–513.
  197. Panici PB, Plotti F, Zullo MA et al (2006) Pelvic lymphadenectomy for cervical carcinoma: laparotomy extra-peritoneal, transperitoneal or laparoscopic approach? A randomized study. *Gynecol Oncol*, 103: 859–864.
  198. Clarke-Pearson DL, DeLong E, Synan IS et al (1990) A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. *Obstet Gynecol*, 75: 684–689.
  199. Clarke-Pearson DL, Synan IS, Dodge R et al (1993) A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. *Am J Obstet Gynecol*, 168: 1146–1154.
  200. Fricker JP, Vergnes Y, Schach R et al (1988) Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. *Eur J Clin Invest*, 18: 561–567.
  201. Heilmann L, von Templehoff GF, Kirkpatrick C et al (1998) Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow-up. *Clin Appl Thromb/Hemost*, 4: 268–273.
  202. Kundu SD, Roehl KA, Eggener SE et al (2004) Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. *J Urol*, 172: 2227–2231.
  203. Pettus JA, Eggener SE, Shabsigh A et al (2006) Perioperative clinical thromboembolic events after radical or partial nephrectomy. *Urology*, 68: 988–992.
  204. Soderdahl DW, Henderson SR, Hansberry KL (1997) A comparison of intermittent pneumatic compression of the calf and whole leg in preventing deep venous thrombosis in urological surgery. *J Urol*, 157: 1774–1776.
  205. Koya MP, Manoharan M, Kim SS et al (2005) Venous thromboembolism in radical prostatectomy: is heparinoid prophylaxis warranted? *BJU Int*, 96: 1019–1021.
  206. Neal DE (1997) The National Prostatectomy Audit. *Br J Urol*, 79 (suppl 2): 69–75.
  207. Rassweiler J, Seemann O, Schulze Met al (2003) Laparoscopic versus open radical prostatectomy: a comparative study at a single institution. *J Urol*, 169: 1689–1693.
  208. Montgomery JS, Wolf JS (2005) Venous thrombosis prophylaxis for urological laparoscopy: fractionated heparin versus sequential compression devices. *J Urol*, 173: 1623–1626.
  209. Pareek G, Hedican SP, Gee JR et al (2006) Meta-analysis of the complications of laparoscopic renal surgery: comparison of procedures and techniques. *J Urol*, 175: 1208–1213.
  210. Toohar R, Swindle P, Woo H et al (2006) Laparoscopic radical prostatectomy for localized prostate cancer: a systematic review of comparative studies. *J Urol*, 175: 2011–2017.
  211. Permpongkosol S, Link RE, Su LM et al (2007) Complications of 2,775 urological laparoscopic procedures: 1993 to 2005. *J Urol*, 177: 580–585.
  212. Kibel AS, Creager MA, Goldhaber SZ et al (1997) Late venous thromboembolic disease after radical prostatectomy: effect of risk factors, warfarin and early discharge. *J Urol*, 158: 2211–2215.
  213. Zacharoulis D, Kakkar AK (2003) Venous thromboembolism in laparoscopic surgery. *Curr Opin Pulm Med*, 9: 356–361.

214. Ljungstrom KG (2005) Is there a need for antithrombotic prophylaxis during laparoscopic surgery? Not always. *J Thromb Haemost*, 3: 212–213.
215. Rasmussen MS (2005) Is there a need for antithrombotic prophylaxis during laparoscopic surgery? Always. *J Thromb Haemost*, 3: 210–211.
216. Society of American Gastrointestinal and Endoscopic Surgeons (2008) Deep venous thrombosis prophylaxis during laparoscopic surgery. Available at: [www.sages.org/sagespublicationprint.php?doc\\_C;2006:1-6](http://www.sages.org/sagespublicationprint.php?doc_C;2006:1-6). Accessed March 31, 2008.
217. Dabrowiecki S, Rosc D, Jurkowski P (1997) The influence of laparoscopic cholecystectomy on perioperative blood clotting and fibrinolysis. *Blood Coagul Fibrinol*, 8: 1–5.
218. Martinez-Ramos C, Lopez-Pastor A, Nunez-Pena JR et al (1999) Changes in hemostasis after laparoscopic cholecystectomy. *Surg Endosc*, 13: 476–479.
219. Prisco D, De Gaudio AR, Carla R et al (2000) Videolaparoscopic cholecystectomy induces a hemostasis activation of lower grade than does open surgery. *Surg Endosc*, 14: 170–174.
220. Nguyen NT, Owings JT, Gosselin R et al (2001) Systemic coagulation and fibrinolysis after laparoscopic and open gastric bypass. *Arch Surg*, 136: 909–916.
221. Podnos YD, Jimenez JC, Wilson SE et al (2003) Complications after laparoscopic gastric bypass: a review of 3464 cases. *Arch Surg*, 138: 957–961.
222. Tincani E, Piccoli M, Turrini F et al (2005) Video laparoscopic surgery: is out-of-hospital thromboprophylaxis necessary? *J Thromb Haemost*, 3: 216–220.
223. Trabulsi EJ, Guillonau B (2005) Laparoscopic radical prostatectomy. *J Urol*, 173: 1072–1079.
224. Lindberg F, Bjorck M, Rasmussen I et al (2006) Low frequency of phlebographic deep vein thrombosis after laparoscopic cholecystectomy: a pilot study. *Clin Appl Thromb/Hemost*, 12: 421–426.
225. Querleu D, Leblanc E, Cartron G et al (2006) Audit of preoperative and early complications of laparoscopic lymph node dissection in 1000 gynecologic cancer patients. *Am J Obstet Gynecol*, 195: 1287–1292.
226. Bounameaux H, Didier D, Polat O et al (1997) Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy. *Thromb Res*, 86: 271–273.
227. Blake AM, Toker SI, Dunn E (2001) Deep venous thrombosis prophylaxis is not indicated for laparoscopic cholecystectomy. *J Soc Laparosc Surg*, 5: 215–219.
228. Catheline JM, Turner R, Gaillard JL et al (1999) Thromboembolism in laparoscopic surgery: risk factors and preventive measures. *Surg Laparosc Endosc Percutan Tech*, 9: 135–139.
229. Chamberlain G, Brown JC (eds) (1978) *Gynecologic laparoscopy: the report of the confidential enquiry into gynaecological laparoscopy*. London, UK: Royal College of Obstetricians and Gynaecologists.
230. Lindberg F, Bergqvist D, Rasmussen I (1997) Incidence of thromboembolic complications after laparoscopic cholecystectomy: review of the literature. *Surg Laparosc Endosc*, 7: 324–331.
231. Caprini JA, Arcelus JJ, Laubach M et al (1995) Postoperative hypercoagulability and deep-vein thrombosis after laparoscopic cholecystectomy. *Surg Endosc*, 9: 304–309.
232. Patel MI, Hardman DT, Nicholls D et al (1996) The incidence of deep venous thrombosis after laparoscopic cholecystectomy. *Med J Aust*, 164: 652–656.
233. Baca I, Schneider B, Kohler T et al (1997) Prevention of venous thromboembolism in patients undergoing minimally invasive surgery with a short-term hospital stay: results of a multicentric, prospective, randomised, controlled clinical trial with a low-molecular-weight heparin. *Chirurg*, 68: 1275–1280.
234. Healey MG, Maher PJ, Hill DJ et al (1998) The risk of venous thrombosis following gynaecological laparoscopic surgery [letter]. *Med J Aust*, 168: 524.
235. Lord RV, Ling JJ, Hugh TB et al (1998) Incidence of deep vein thrombosis after laparoscopic vs minilaparotomy cholecystectomy. *Arch Surg*, 133: 967–973.
236. Wazz G, Branicki F, Taji H et al (2000) Influence of pneumoperitoneum on the deep venous system during laparoscopy. *J Soc Laparosc Surg*, 4: 291–295.
237. Mall JW, Schwenk W, Rodiger O et al (2001) Blinded prospective study of the incidence of deep venous thrombosis following conventional or laparoscopic colorectal resection. *Br J Surg*, 88: 99–100.
238. Schaepekens van Riepst JT, Van Hee RH, Weyler JJ (2002) Deep venous thrombosis after laparoscopic cholecystectomy and prevention with nadroparin. *Surg Endosc*, 16: 184–187.
239. Schwenk W, Bohm B, Fugener A et al (1998) Intermittent pneumatic sequential compression (ISC) of the lower extremities prevents venous stasis during laparoscopic cholecystectomy: a prospective randomized study. *Surg Endosc*, 12: 7–11.
240. Isoda N, Suzuki T, Ido K et al (2000) Femoral vein stasis during laparoscopic cholecystectomy: effect of an intermittent sequential pneumatic compression device. *Digest Endosc*, 12: 225–228.
241. Neudecker J, Sauerland S, Neugebauer E et al (2002) The European Association for Endoscopic Surgery clinical practice guideline on the pneumoperitoneum for laparoscopic surgery. *Surg Endosc* 2002; 16: 1121–1143.
242. Bergqvist D, Lowe G (2002) Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. *Arch Intern Med*, 162: 2173–2176.
243. Steinbrook R (2004) Surgery for severe obesity. *N Engl J Med*, 350: 1075–1079.
244. DeMaria EJ (2007) Bariatric surgery for morbid obesity. *N Engl J Med*, 356: 2176–2183.
245. Prystowsky JB, Morasch MD, Eskandari MK et al (2005) Prospective analysis of the incidence of deep venous thrombosis in bariatric surgery patients. *Surgery*, 138: 759–763.
246. McCarty TM, Arnold DT, Lamont JP et al (2005) Optimizing outcomes in bariatric surgery: outpatient laparoscopic gastric bypass. *Ann Surg*, 242: 494–498.
247. Rocha AT, de Vasconcellos AG, da Luz Neto ER et al (2006) Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. *Obes Surg*, 16: 1645–1655.
248. Mason EE, Tang S, Renquist KE et al (1997) A decade of change in obesity surgery. *Obes Surg*, 7: 189–197.

249. Poulouse BK, Griffin MR, Zhu Y et al (2005) National analysis of adverse patient safety events in bariatric surgery. *Am Surg*, 71: 406–413.
250. Fernandez AZ, Demaria EJ, Tichansky DS et al (2004) Multivariate analysis of risk factors for death following gastric bypass for treatment of morbid obesity. *Ann Surg*, 239: 698–702.
251. Smith SC, Edwards CB, Goodman GN et al (2004) Open vs laparoscopic Roux-en-Y gastric bypass: comparison of operative morbidity and mortality. *Obes Surg*, 14: 73–76.
252. Sapala JA, Wood MH, Schuhknecht MP et al (2003) Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. *Obes Surg*, 13: 819–825.
253. Hamad GG, Choban PS (2005) Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. *Obes Surg*, 15: 1368–1374.
254. Gonzalez R, Haines K, Nelson LG et al (2006) Predictive factors of thromboembolic events in patients undergoing Roux-en-Y gastric bypass. *Surg Obes Relat Dis*, 2: 30–35.
255. Wu EC, Barba CA (2000) Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. *Obes Surg*, 10: 7–13.
256. Kalfarentzos F, Stavropoulou F, Yarmenitis S et al (2001) Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial. *Obes Surg*, 11: 670–676.
257. Scholten DJ, Hoedema RM, Scholten SE (2002) A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. *Obes Surg*, 12: 19–24.
258. Frederiksen SG, Hedenbro JL, Norgren L (2003) Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. *Br J Surg*, 90: 547–548.
259. Shepherd MF, Rosborough TK, Schwartz ML (2004) Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. *Obes Surg*, 14: 601–605.
260. Quebbemann B, Akhondzadeh M, Dallal R (2005) Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. *Obes Surg*, 15: 1221–1224.
261. Shepherd MF, Rosborough TK, Schwartz ML (2003) Heparin thromboprophylaxis in gastric bypass surgery. *Obes Surg*, 13: 249–253.
262. Ziomek S, Read RC, Tobler HG et al (1993) Thromboembolism in patients undergoing thoracotomy. *Ann Thorac Surg*, 56: 223–226.
263. Nagahiro I, Andou A, Aoe M et al (2004) Intermittent pneumatic compression is effective in preventing symptomatic pulmonary embolism after thoracic surgery. *Surg Today*, 34: 6–10.
264. Kalweit G, Huwer H, Volkmer I et al (1996) Pulmonary embolism: a frequent cause of acute fatality after lung resection. *Eur J Cardiothorac Surg*, 10: 242–246.
265. Jackaman FR, Perry BJ, Siddons H (1978) Deep vein thrombosis after thoracotomy. *Thorax*, 33: 761–763.
266. Ljungstrom KG (1985) Deep-vein thrombosis after major noncardiovascular thoracic surgery. *Scand J Thorac Cardiovasc Surg*, 19: 161–164.
267. Saarinen J, Kallio T, Sisto T et al (2001) Incidence of deep venous thrombosis after thoracotomy. *VASA*, 30: 259–261.
268. Mason DP, Quader MA, Blackstone EH et al (2006) Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. *J Thorac Cardiovasc Surg*, 131: 711–718.
269. Sugarbaker DJ, Jaklitsch MT, Bueno R et al (2004) Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. *J Thorac Cardiovasc Surg*, 128: 138–146.
270. Cade JF, Clegg EA, Westlake GW (1983) Prophylaxis of venous thrombosis after major thoracic surgery. *Aust N Z J Surg*, 53: 301–304.
271. Azorin JF, Regnard JF, Dahan M et al (1997) Efficacy and tolerability of Fraxiparine in the prevention of thromboembolic events in lung cancer. *Ann Cardiol Angiol*, 46: 341–347.
272. Goldhaber SZ, Schoepf UJ (2004) Pulmonary embolism after coronary artery bypass grafting. *Circulation*, 109: 2712–2715.
273. Josa M, Siouffi SY, Silverman AB et al (1993) Pulmonary embolism after cardiac surgery. *J Am Coll Cardiol*, 21: 990–996.
274. Reis SE, Polak JF, Hirsch DR et al (1991) Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. *Am Heart J*, 122: 478–482.
275. Goldhaber SZ, Hirsch DR, MacDougall RC et al (1995) Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). *Am J Cardiol*, 76: 993–996.
276. Ambrosetti M, Salerno M, Zambelli M et al (2004) Deep vein thrombosis among patients entering cardiac rehabilitation after coronary artery bypass surgery. *Chest*, 125: 191–196.
277. DeLaria GA, Hunter JA (1991) Deep venous thrombosis: implications after open heart surgery. *Chest*, 99: 284–288.
278. Gillinov AM, Davis EA, Alberg AJ et al (1992) Pulmonary embolism in the cardiac surgical patient. *Ann Thorac Surg*, 53: 988–991.
279. Cartier R, Robitaille D (2001) Thrombotic complications in beating heart operations. *J Thorac Cardiovasc Surg*, 121: 920–922.
280. Hannan EL, Racz MJ, Walford G et al (2003) Predictors of readmission for complications of coronary artery bypass graft surgery. *JAMA*, 290: 773–780.
281. Smythe MA, Koerber JM, Mattson JC (2007) The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. *Chest*, 131: 1644–1649.
282. Pouplard C, May MA, Lochmann S et al (1999) Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. *Circulation*, 99: 2530–2536.
283. Kuitunen A, Suojaranta-Ylinen R, Raivio P et al (2007) Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome. *J Cardiothorac Vasc Anesth*, 21: 18–22.



284. National Institutes of Health Consensus Conference (1986) Prevention of venous thrombosis and pulmonary embolism. *JAMA*, 256: 744–749.
285. Warwick D (2004) New concepts in orthopaedic thromboprophylaxis. *J Bone Joint Surg Br*, 86: 788–792.
286. Dahl OE, Caprini JA, Colwell CW et al (2005) Fatal vascular outcomes following major orthopedic surgery. *Thromb Haemost*, 93: 860–866.
287. Lieberman JR, Hsu WK (2005) Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *J Bone Joint Surg Am*, 87: 2097–2112.
288. Cordell-Smith JA, Williams SC, Harper WM et al (2004) Lower limb arthroplasty complicated by deep venous thrombosis: prevalence and subjective outcome. *J Bone Joint Surg Br*, 86: 99–101.
289. Seagroatt V, Tan HS, Goldacre M (1991) Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. *BMJ*, 303: 1431–1435.
290. Lieberman JR, Sung R, Dorey F et al (1997) Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty. *J Arthroplasty*, 12: 180–184.
291. Lieberman JR, Wollaeger J, Dorey F et al (1997) The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. *J Bone Joint Surg Am*, 79: 319–325.
292. Turpie AG, Bauer KA, Eriksson BI et al (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. *Arch Intern Med*, 162: 1833–1840.
293. Howie C, Hughes H, Watts AC (2005) Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. *J Bone Joint Surg Br*, 87: 1675–1680.
294. Lotke PA, Lonner JH (2006) The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. *Clin Orthop*, 452: 175–180.
295. Pellegrini VD, Donaldson CT, Farber DC et al (2006) The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. *Clin Orthop*, 452: 21–27.
296. Warwick DJ, Whitehouse S (1997) Symptomatic venous thromboembolism after total knee replacement. *J Bone Joint Surg Br*, 78: 780–786.
297. Leclerc JR, Gent M, Hirsh J et al (1998) The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. *Arch Intern Med*, 158: 873–878.
298. Colwell CW, Collis DK, Paulson R et al (1999) Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. *J Bone Joint Surg Am*, 81: 932–940.
299. Dahl OE, Gudmundsen TE, Haukeland L (2000) Late occurring clinical deep vein thrombosis in joint-operated patients. *Acta Orthop Scand*, 71: 47–50.
300. Heit JA, Elliott CG, Trowbridge AA et al (2000) Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med*, 132: 853–861.
301. Anderson DR, Wilson SJ, Blundell J et al (2002) Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. *J Bone Joint Surg Am*, 84: 1992–1997.
302. Pellegrini VD, Clement D, Lush-Ehmann C et al (1996) Natural history of thromboembolic disease after total hip arthroplasty. *Clin Orthop*, 333: 27–40.
303. White RH, Romano PS, Zhou H et al (1998) Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. *Arch Intern Med*, 158: 1525–1531.
304. Douketis JD, Eikelboom JW, Quinlan DJ et al (2002) Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. *Arch Intern Med*, 162: 1465–1471.
305. Bjornara BT, Gudmundsen TE, Dahl OE (2006) Frequency and timing of clinical venous thromboembolism after major joint surgery. *J Bone Joint Surg Br*, 88: 386–391.
306. Ginsberg JS, Gent M, Turkstra F et al (2000) Post-thrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. *Arch Intern Med*, 160: 669–672.
307. Kim YH, Oh SH, Kim JS (2003) Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. *J Bone Joint Surg Br*, 85: 661–665.
308. Buehler KO, D'Lima DD, Petersilge WJ et al (1999) Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty. *Clin Orthop*, 361: 123–130.
309. Lindahl TL, Lundahl TH, Nilsson L et al (1999) APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee: a prospective study. *Thromb Haemost*, 81: 18–21.
310. Westrich GH, Weksler BB, Glueck CJ et al (2002) Correlation of thrombophilia and hypofibrinolysis with pulmonary embolism following total hip arthroplasty: an analysis of genetic factors. *J Bone Joint Surg Am*, 84: 2161–2167.
311. Wilson D, Cooke EA, McNally MA et al (2002) Altered venous function and deep venous thrombosis following proximal femoral fracture. *Injury*, 33: 33–39.
312. Maynard MJ, Sculco TP, Ghelman B (1991) Progression and regression of deep vein thrombosis after total knee arthroplasty. *Clin Orthop*, 273: 125–130.
313. Planes A, Vochelle N, Darmon JY et al (1996) Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. *Lancet*, 348: 224–228.
314. Beksas B, Della Valle AG, Salvati EA (2006) Thromboembolic disease after total hip arthroplasty: who is at risk? *Clin Orthop*, 453: 211–224.
315. Patel VP, Walsh M, Sehgal B et al (2007) Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. *J Bone Joint Surg Am*, 89: 33–38.
316. Saleh K, Olson M, Resig S et al (2002) Predictors of wound infection in hip and knee joint replacement: results from a 20 year surveillance program. *J Orthop Res*, 20: 506–515.
317. Kurtz S, Mowat F, Ong K et al (2005) Prevalence of primary and revision total hip and knee arthroplasty in the United

- States from 1990 through 2002. *J Bone Joint Surg Am*, 87: 1487–1497.
318. Kurtz S, Ong K, Lau E et al (2007) Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am*, 89: 780–785.
319. Salvati EA, Pellegrini VD, Sharrock NE et al (2000) Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. *J Bone Joint Surg Am*, 82: 252–270.
320. Phillips CB, Barrett JA, Losina E et al (2003) Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. *J Bone Joint Surg Am*, 85: 20–26.
321. Warwick D, Williams MH, Bannister GC (1995) Death and thromboembolic disease after total hip replacement: a series of 1162 cases with no routine chemical prophylaxis. *J Bone Joint Surg Br*, 77: 6–10.
322. Fender D, Harper WM, Thompson JR et al (1997) Mortality and fatal pulmonary embolism after primary total hip replacement: results from a regional hip register. *J Bone Joint Surg Br*, 79: 896–899.
323. Wroblewski BM, Siney PD, Fleming PA (1998) Fatal pulmonary embolism after total hip arthroplasty: diurnal variations. *Orthopedics*, 21: 1269–1271.
324. Gillespie W, Murray D, Gregg PJ et al (2000) Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. *J Bone Joint Surg Br*, 82: 475–479.
325. Samama CM, Clergue F, Barre J et al (1997) Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery. *Br J Anaesth*, 78: 660–665.
326. Mismetti P, Laporte S, Zufferey P et al (2004) Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. *J Thromb Haemost*, 2: 1058–1070.
327. Fordyce MJ, Ling RS (1992) A venous foot pump reduces thrombosis after total hip replacement. *J Bone Joint Surg Br*, 74: 45–49.
328. Warwick D, Harrison J, Glew D et al (1998) Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. *J Bone Joint Surg Am*, 80: 1158–1166.
329. Pitto RP, Hamer H, Heiss-Dunlop W et al (2004) Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. *J Bone Joint Surg Br*, 86: 639–642.
330. Ryan MG, Westrich GH, Potter HG et al (2002) Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. *J Bone Joint Surg Am*, 84: 1998–2004.
331. Lachiewicz PF, Soileau ES (2006) Multimodal prophylaxis for THA with mechanical compression. *Clin Orthop*, 453: 225–230.
332. Keeney JA, Clohisy JC, Curry MC et al (2006) Efficacy of combined modality prophylaxis including short-duration warfarin to prevent venous thromboembolism after total hip arthroplasty. *J Arthroplasty*, 21: 469–475.
333. Sarmiento A, Goswami A (2005) Thromboembolic disease prophylaxis in total hip arthroplasty. *Clin Orthop*, 436: 138–143.
334. Salvati EA, Sharrock NE, Westrich G et al (2007) Three decades of clinical, basic, and applied research on thromboembolic disease after THA: rationale and clinical results of a multimodal prophylaxis protocol. *Clin Orthop*, 459: 246–254.
335. Gonzalez Della Valle A, Serota A, Go G et al (2006) Venous thromboembolism is rare with a multimodal prophylaxis protocol after total hip arthroplasty. *Clin Orthop*, 444: 146–153.
336. Mesko JW, Brand RA, Iorio R et al (2001) Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. *J Arthroplasty*, 16: 679–688.
337. Samama CM, Vray M, Barre J et al (2002) Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Arch Intern Med*, 162: 2191–2196.
338. RD Heparin Arthroplasty Group (1994) RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. *J Bone Joint Surg Am*, 76: 1174–1185.
339. Francis CW, Pellegrini VD, Totterman S et al (1997) Prevention of deep-vein thrombosis after total hip arthroplasty: comparison of warfarin and dalteparin. *J Bone Joint Surg Am*, 79: 1365–1372.
340. Caprini JA, Arcelus JI, Motykie G et al (1999) The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. *J Vasc Surg*, 30: 813–820.
341. Asnis PD, Gardner MJ, Ranawat A et al (2007) The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. *J Arthroplasty*, 22: 213–218.
342. Planes A, Vochelle N, Mazas F et al (1988) Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. *Thromb Haemost*, 60: 407–410.
343. German Hip Arthroplasty Trial (GHAT) Group (1992) Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. *Arch Orthop Trauma Surg*, 111: 110–120.
344. Colwell CW, Spiro TE, Trowbridge AA et al (1994) Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. *J Bone Joint Surg Am*, 76: 3–14.
345. Hull R, Raskob G, Pineo G et al (1993) A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. *N Engl J Med*, 329: 1370–1376.
346. Hamulyak K, Lensing AW, van der Meer J et al (1995) Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? *Thromb Haemost*, 74: 1428–1431.
347. Hull RD, Pineo GF, Francis C et al (2000) Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a doubleblind, randomized comparison. *Arch Intern Med*, 160: 2199–2207.

348. Turpie AG, Levine MN, Hirsh J et al (1986) A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. *N Engl J Med*, 315: 925–929.
349. Colwell CW Jr., Spiro TE (1995) Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. *Clin Orthop Relat Res*, 319: 215–222.
350. O'Donnell M, Julian J, Kearon C (2005) Risk of bleeding with vitamin K antagonists compared with low-molecular-weight heparin after orthopedic surgery: a rebuttal. *J Thromb Haemost*, 3: 606–608.
351. Lassen MR, Bauer KA, Eriksson BI et al (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. *Lancet*, 359: 1715–1720.
352. Turpie AG, Bauer KA, Eriksson BI et al (2002) Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. *Lancet*, 359: 1721–1726.
353. Turpie AG, Bauer KA, Eriksson BI et al (2004) Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. *Chest*, 126: 501–508.
354. Bauer KA, Eriksson BI, Lassen MR et al (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. *N Engl J Med*, 345: 1305–1310.
355. Eriksson BI, Bauer KA, Lassen MR et al (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. *N Engl J Med*, 345: 1298–1304.
356. Colwell CW Jr, Kwong LM, Turpie AG et al (2006) Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. *J Arthroplasty*, 21: 36–45.
357. Eriksson BI, Bergqvist D, Kalebo P et al (2002) Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. *Lancet*, 360: 1441–1447.
358. Eriksson BI, Agnelli G, Cohen AT et al (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or total knee replacement: the EXPRESS Study. *J Thromb Haemost*, 1: 2490–2496.
359. Eriksson BI, Agnelli G, Cohen AT et al (2003) Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or total knee replacement: the METHRO III study. *Thromb Haemost*, 89: 288–296.
360. Colwell CW, Berkowitz SD, Davidson BL et al (2003) Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. *J Thromb Haemost*, 1: 2119–2130.
361. Hull R, Delmore TJ, Hirsh J et al (1979) Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. *Thromb Res*, 16: 37–45.
362. Haas SB, Insall JN, Scuderi GR et al (1990) Pneumatic sequential compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. *J Bone Joint Surg Am*, 72: 27–31.
363. Kaempffe FA, Lifeso RM, Meinking C (1991) Intermittent pneumatic compression versus Coumadin: prevention of deep vein thrombosis in low-extremity total joint arthroplasty. *Clin Orthop*, 269: 89–97.
364. Wilson NV, Das SK, Kakkar VV et al (1992) Thrombo-embolic prophylaxis in total knee replacement: evaluation of the A-V Impulse System. *J Bone Joint Surg Br*, 74: 50–52.
365. Norgren L, Toksvig-Larsen S, Magyar G et al (1998) Prevention of deep vein thrombosis in knee arthroplasty: preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. *Int Angiol*, 17: 93–96.
366. Warwick D, Harrison J, Whitehouse S et al (2002) A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. *J Bone Joint Surg Br*, 84: 344–350.
367. Levine MN, Gent M, Hirsh J et al (1996) Ardeparin (lowmolecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism: a randomized trial in patients undergoing knee surgery. *Arch Intern Med*, 156: 851–856.
368. Hui AC, Heras-Palou C, Dunn I et al (1996) Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. *J Bone Joint Surg Br*, 78: 550–554.
369. Colwell CW, Spiro TE, Trowbridge AA et al (1995) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. *Clin Orthop*, 321: 19–27.
370. Fauno P, Suomalainen O, Rehnberg V et al (1994) Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty: a comparison between unfractionated and lowmolecular-weight heparin. *J Bone Joint Surg Am*, 76: 1814–1818.
371. Lynch AF, Bourne RB, Rorabeck CH et al (1988) Deep-vein thrombosis and continuous passive motion after total knee arthroplasty. *J Bone Joint Surg Am*, 70: 11–14.
372. Francis CW, Pellegrini VD, Leibert KM et al (1996) Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. *Thromb Haemost*, 75: 706–711.
373. Leclerc JR, Geerts WH, Desjardins L et al (1996) Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. *Ann Intern Med*, 124: 619–626.
374. Heit JA, Berkowitz SD, Bona R et al (1997) Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, doseranging study. *Thromb Haemost*, 77: 32–38.
375. Fitzgerald RH, Spiro TE, Trowbridge AA et al (2001) Prevention of venous thromboembolic disease following pri-

- mary total knee arthroplasty: a randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *J Bone Joint Surg Am*, 83: 900–906.
376. Francis CW, Davidson BL, Berkowitz SD et al (2002) Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. *Ann Intern Med*, 137: 648–655.
  377. Francis CW, Berkowitz SD, Comp PC et al (2003) Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. *N Engl J Med*, 349: 1703–1712.
  378. Colwell CW, Berkowitz SD, Lieberman JR et al (2005) Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. *J Bone Joint Surg Am*, 87: 2169–2177.
  379. Robinson KS, Anderson DR, Gross M et al (1997) Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the Post-Arthroplasty Screening Study: a randomized, controlled trial. *Ann Intern Med*, 127: 439–445.
  380. Leclerc JR, Geerts WH, Desjardins L et al (1992) Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. *Thromb Haemost*, 67: 417–423.
  381. Heit JA, Colwell CW, Francis CW et al (2001) Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. *Arch Intern Med*, 161: 2215–2221.
  382. Navarro-Quilis A, Castellet E, Rocha E et al (2003) Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. *J Thromb Haemost*, 1: 425–432.
  383. Colwell CW, Hardwick ME (2006) Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty. *Clin Orthop*, 452: 181–185.
  384. Howard AW, Aaron SD (1998) Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty: a meta-analysis of randomized trials. *Thromb Haemost*, 79: 902–906.
  385. Brookenthal KR, Freedman KB, Lotke PA et al (2001) A metaanalysis of thromboembolic prophylaxis in total knee arthroplasty. *J Arthroplasty*, 16: 293–300.
  386. Kraay MJ, Goldberg VM, Herbener TE (1993) Vascular ultrasonography for deep venous thrombosis after total knee arthroplasty. *Clin Orthop*, 286: 18–26.
  387. Woolson ST, Robinson RK, Khan NQ et al (1998) Deep venous thrombosis prophylaxis for knee replacement: warfarin and pneumatic compression. *Am J Orthop*, 27: 299–304.
  388. Westrich GH, Menezes A, Sharrock N et al (1999) Thromboembolic disease prophylaxis in total knee arthroplasty using intraoperative heparin and postoperative pneumatic foot compression. *J Arthroplasty*, 14: 651–656.
  389. Mant MJ, Russell DB, Johnston DW et al (2000) Intraoperative heparin in addition to postoperative low-molecular-weight heparin for thromboprophylaxis in total knee replacement. *J Bone Joint Surg Br*, 82: 48–49.
  390. Ragucci MV, Leali A, Moroz A et al (2003) Comprehensive deep venous thrombosis prevention strategy after total-knee arthroplasty. *Am J Phys Med Rehabil*, 82: 164–168.
  391. Reitman RD, Emerson RH, Higgins LL et al (2003) A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. *J Arthroplasty*, 18: 161–168.
  392. Westrich GH, Bottner F, Windsor RE et al (2006) VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. *J Arthroplasty*, 21: 139–143.
  393. Hoppener MR, Ettema HB, Kraaijenhagen RA et al (2003) Day-care or short-stay surgery and venous thromboembolism. *J Thromb Haemost*, 1: 863–865.
  394. Ilahi OA, Reddy J, Ahmad I (2005) Deep venous thrombosis after knee arthroscopy: a meta-analysis. *Arthroscopy*, 21: 727–730.
  395. Ettema HB, Hoppener MR, Veeger NJ et al (2006) Low incidence of venographically detected deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study. *J Thromb Haemost*, 4: 1411–1413.
  396. Hoppener MR, Ettema HB, Henny CP et al (2006) Low incidence of deep vein thrombosis after knee arthroscopy without thromboprophylaxis: a prospective cohort study of 335 patients. *Acta Orthop*, 77: 767–771.
  397. Demers C, Marcoux S, Ginsberg JS et al (1998) Incidence of venographically proved deep vein thrombosis after knee arthroscopy. *Arch Intern Med*, 158: 47–50.
  398. Jaureguito JW, Greenwald AE, Wilcox JF et al (1999) The incidence of deep venous thrombosis after arthroscopic knee surgery. *Am J Sports Med*, 27: 707–710.
  399. Wirth T, Schneider B, Misselwitz F et al (2001) Prevention of venous thromboembolism after knee arthroscopy with lowmolecular weight heparin (reviparin): results of a randomized controlled trial. *Arthroscopy*, 17: 393–399.
  400. Michot M, Conen D, Holtz D et al (2002) Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomized trial of prophylaxis with low-molecular weight heparin. *Arthroscopy*, 18: 257–263.
  401. Camporese G, Bernardi E, Prandoni P et al (2007) Graduated compression stocking (GCS) versus low-molecular-weight heparin (LMWH) for prevention of deep vein thrombosis (DVT) after knee arthroscopy (KA): a randomized study (KANT). *J Thromb Haemost*, 5 (suppl 2): OT-052.
  402. Ramos J, Perrotta C, Badariotti G et al (2007) Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. *Cochrane Database Syst Rev*, 2: CD005259.
  403. Ageno W, Dentali F, Imberti D (2004) A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery. *J Thromb Haemost*, 2: 1901–1902.
  404. Hoppener MR, Ettema HB, Henny CP et al (2005) Symptomatic deep vein thrombosis and immobilization after day-care arthroscopy of the knee. *J Thromb Haemost*, 3: 185–187.
  405. Hitos K, Fletcher JP (2005) Venous thromboembolism and fractured neck of femur. *Thromb Haemost*, 94: 991–996.
  406. Rosencher N, Vielpeau C, Emmerich J et al (2005) Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. *J Thromb Haemost*, 3: 2006–2014.

407. McLaughlin MA, Orosz GM, Magaziner J et al (2006) Preoperative status and risk of complications in patients with hip fracture. *J Gen Intern Med*, 21: 219–225.
408. Haake DA, Berkman SA (1989) Venous thromboembolic disease after hip surgery: risk factors, prophylaxis, and diagnosis. *Clin Orthop*, 242: 212–231.
409. Todd CJ, Freeman CJ, Camilleri-Ferrante C et al (1995) Differences in mortality after fracture of hip: the East Anglian audit. *BMJ*, 310: 904–908.
410. Schroder HM, Andreassen M (1993) Autopsy-verified major pulmonary embolism after hip fracture. *Clin Orthop*, 293: 196–203.
411. Perez JV, Warwick DJ, Case CP et al (1995) Death after proximal femoral fracture - an autopsy study. *Injury*, 26: 237–240.
412. Hefley WF, Nelson CL, Puskarich-May CL (1996) Effect of delayed admission to the hospital on the preoperative prevalence of deep-vein thrombosis associated with fractures about the hip. *J Bone Joint Surg Am*, 78: 581–583.
413. Zahn HR, Skinner JA, Porteous MJ (1999) The preoperative prevalence of deep vein thrombosis in patients with femoral neck fractures and delayed operation. *Injury*, 30: 605–607.
414. Sevitt S, Gallagher NG (1959) Prevention of venous thrombosis and pulmonary embolism in injured patients: a trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of femur. *Lancet*, ii: 981–989.
415. Fisher CG, Blachut PA, Salvian AJ et al (1995) Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. *J Orthop Trauma*, 9: 1–7.
416. Westrich GH, Rana AJ, Terry MA et al (2005) Thromboembolic disease prophylaxis in patients with hip fracture: a multimodal approach. *J Orthop Trauma*, 19: 234–240.
417. Monreal M, Lafoz E, Navarro A et al (1989) A prospective double-blind trial of a low molecular weight heparin once daily compared with conventional low-dose heparin three times daily to prevent pulmonary embolism and venous thrombosis in patients with hip fracture. *J Trauma*, 29: 873–875.
418. Barsotti J, Gruel Y, Rosset P et al (1990) Comparative doubleblind study of two dosage regimens low-molecular weight heparin in elderly patients with a fracture of the neck of the femur. *J Orthop Trauma*, 4: 371–375.
419. Jorgensen PS, Strandberg C, Willie-Jorgensen P et al (1998) Early preoperative thromboprophylaxis with Klexane in hip fracture surgery: a placebo-controlled study. *Clin Appl Thromb Haemost*, 4: 140–142.
420. TIFDED Study Group (1990) Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. *Haemostasis*, 29: 310–317.
421. Borgstrom S, Greitz T, van der Linden W et al (1965) Anticoagulant prophylaxis of venous thrombosis in patients with fractured neck of the femur: a controlled clinical trial using venous phlebography. *Acta Chir Scand*, 129: 500–508.
422. Hamilton HW, Crawford JS, Gardiner JH et al (1970) Venous thrombosis in patients with fracture of the upper end of the femur: a phlebographic study of the effect of prophylactic anticoagulation. *J Bone Joint Surg*, 52-B: 268–289.
423. Eriksson BI, Lassen MR, for the Pentasaccharide in Hip-Fracture Surgery Plus (PENTHIFRA Plus) Investigators (2003) Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. *Arch Intern Med*, 163: 1337–1342.
424. Roberts TS, Nelson CL, Barnes CL et al (1990) The preoperative prevalence and postoperative incidence of thromboembolism in patients with hip fractures treated with dextran prophylaxis. *Clin Orthop*, 255: 198–203.
425. Girasole GJ, Cuomo F, Denton JR et al (1994) Diagnosis of deep vein thrombosis in elderly hip-fracture patients by using the duplex scanning technique. *Orthop Rev*, 23: 411–416.
426. Raskob GE, Hirsh J (2003) Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. *Chest*, 124 (suppl): 379S–385S.
427. Hull RD, Pineo GF, Francis C et al (2000) Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. *Arch Intern Med*, 160: 2208–2215.
428. Strebel N, Prins M, Agnelli G et al (2002) Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? *Arch Intern Med*, 162: 1451–1456.
429. Hull RD, Pineo GF, Stein PD et al (2001) Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. *Arch Intern Med*, 161: 1952–1960.
430. Eriksson BI, Wille-Jorgensen P, Kalebo P et al (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. *N Engl J Med*, 337: 1329–1335.
431. Cohen AT, Hirst C, Sherrill B et al (2005) Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. *Br J Surg*, 92: 1335–1344.
432. Berry DJ (2001) Surveillance for venous thromboembolic disease after total knee arthroplasty. *Clin Orthop*, 392: 257–266.
433. Schmidt B, Michler R, Klein M et al (2003) Ultrasound screening for distal vein thrombosis is not beneficial after major orthopedic surgery: a randomized controlled trial. *Thromb Haemost*, 90: 949–954.
434. Schwarcz TH, Matthews MR, Hartford JM et al (2004) Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used. *Ann Vasc Surg*, 18: 193–198.
435. Dhupar S, Iorio R, Healy WL et al (2006) A comparison of discharge and two-week duplex ultrasound screening protocols for deep venous thrombosis detection following primary total joint arthroplasty. *J Bone Joint Surg Am*, 88: 2380–2385.

436. Iorio R, Dhupar S, Healy WL et al (2006) Routine duplex ultrasound screening after TKA is not necessary. *Clin Orthop*, 452: 171–174.
437. Verlato F, Bruchi O, Prandoni P et al (2001) The value of ultrasound screening for proximal vein thrombosis after total hip arthroplasty: a prospective cohort study. *Thromb Haemost*, 86: 534–537.
438. Schellong S, Hesselschwerdt HJ, Paar WD et al (2005) Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery. *Thromb Haemost*, 94: 532–536.
439. Kearon C (2003) Duration of venous thromboembolism prophylaxis after surgery. *Chest*, 124 (suppl): 386S–392S.
440. Anderson FA, White K, for the Hip and Knee Registry Investigators (2002) Prolonged prophylaxis in orthopedic surgery: insights from the United States. *Semin Thromb Haemost*, 28 (suppl 3): 43–46.
441. Dahl OE, Andreassen G, Aspelin T et al (1997) Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). *Thromb Haemost*, 77: 26–31.
442. Planes A, Samama MM, Lensing AW et al (1999) Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular heparins, tinzaparin and enoxaparin. *Thromb Haemost*, 81: 22–25.
443. Dahl OE, Aspelin T, Arnesen H et al (1995) Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. *Thromb Res*, 80: 299–306.
444. Arnesen H, Dahl OE, Aspelin T et al (2003) Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. *J Thromb Haemost*, 1: 971–975.
445. Sikorski JM, Hampson WG, Staddon GE (1981) The natural history and aetiology of deep vein thrombosis after total hip replacement. *J Bone Joint Surg Br*, 63: 171–177.
446. Lotke PA, Steinberg ME, Ecker ML (1994) Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty. *Clin Orthop*, 229: 25–30.
447. Trowbridge A, Boese CK, Woodruff B et al (1994) Incidence of posthospitalization proximal deep venous thrombosis after total hip arthroplasty: a pilot study. *Clin Orthop*, 299: 203–208.
448. Bergqvist D, Benoni G, Bjorgell O et al (1996) Low-molecularweight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *N Engl J Med*, 335: 696–700.
449. White RH, Gettner S, Newman JM et al (2000) Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. *N Engl J Med*, 343: 1758–1764.
450. Lassen MR, Borris LC, Anderson BS et al (1998) Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) Study. *Thromb Res*, 89: 281–287.
451. Comp PC, Spiro TE, Friedman RJ et al (2001) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. *J Bone Joint Surg Am*, 83: 336–345.
452. Hull RD, Pineo GF, Stein PD et al (2001) Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. *Ann Intern Med*, 135: 858–869.
453. Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. *Lancet*, 358: 9–15.
454. Cohen AT, Bailey CS, Alikhan R et al (2001) Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. *Thromb Haemost*, 85: 940–941.
455. Skedgel C, Goeree R, Pleasance S et al (2007) The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. *J Bone Joint Surg Am*, 89: 819–828.
456. O'Donnell M, Linkins LA, Kearon C et al (2003) Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. *Arch Intern Med*, 163: 1362–1366.
457. Prandoni P, Bruchi O, Sabbion P et al (2002) Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. *Arch Intern Med*, 162: 1966–1971.
458. Kolb G, Bodamer I, Galster H et al (2003) Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. *Thromb Haemost*, 90: 1100–1105.
459. Marchetti M, Liberato NL, Ruperto N et al (1994) Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. *Haematologica*, 84: 730–737.
460. Friedman RJ, Dunsworth GA (2000) Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. *Clin Orthop*, 370: 171–182.
461. Sarasin FP, Bounameaux H (2002) Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecularweight heparin, warfarin, aspirin or nothing? A costeffectiveness analysis. *Thromb Haemost*, 87: 586–592.
462. Haentjens P, De Groote K, Annemans L (2004) Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement: a cost-utility analysis. *Arch Orthop Trauma Surg*, 124: 507–517.
463. Heit JA (2001) Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. *Thromb Res*, 101: V163–V173.
464. Brotman DJ, Jaffer AK, Hurbaneck JG et al (2004) Warfarin prophylaxis and venous thromboembolism in the

- first 5 days following hip and knee arthroplasty. *Thromb Haemost*, 92: 1012–1017.
465. Catre MG (1997) Anticoagulation in spinal surgery: a critical review of the literature. *Can J Surg*, 40: 413–419.
  466. Brambilla S, Ruosi C, La Maida GA et al (2004) Prevention of venous thromboembolism in spinal surgery. *Eur Spine J*, 13: 1–8.
  467. Gallus AS, Hirsh J, O'Brien SE et al (1976) Prevention of venous thrombosis with small, subcutaneous doses of heparin. *JAMA*, 235: 1980–1982.
  468. Macouillard G, Castagnera L, Claverie JP et al (1993) Prevention of deep venous thrombosis in spinal surgery: comparison of intermittent sequential pneumatic compression versus low molecular weight heparin [abstract]. *Thromb Haemost*, 69: 646.
  469. Rokito SE, Schwartz MC, Neuwirth MG (1996) Deep vein thrombosis after major reconstructive spinal surgery. *Spine*, 21: 853–859.
  470. Kujath P, Spannagel U, Habscheid W (1993) Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. *Haemostasis*, 23 (suppl 1): 20–26.
  471. Kock HJ, Schmit-Neuerburg KP, Hanke J et al (1995) Thromboprophylaxis with low-molecular-weight heparin in outpatients with plaster-cast immobilisation of the leg. *Lancet*, 346: 459–461.
  472. Selby R, Geerts WH, Crowther MA et al (2005) A prospective cohort study of the epidemiology of symptomatic thromboembolism (VTE) after isolated leg fractures distal to the knee without thromboprophylaxis [abstract]. *Blood*, 106: 583.
  473. Abelseth G, Buckley RE, Pineo GE et al (1996) Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. *J Orthop Trauma*, 10: 230–235.
  474. Lassen MR, Borris LC, Nakov RL (2002) Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization. *N Engl J Med*, 347: 726–730.
  475. Jorgensen PS, Warming T, Hansen K et al (2002) Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venographic controlled study. *Thromb Res*, 105: 477–480.
  476. Lapidus LJ, Rosfors S, Ponzer S et al (2007) Prolonged thromboprophylaxis with dalteparin after surgical treatment of Achilles tendon rupture: a randomized, placebo-controlled study. *J Orthop Trauma*, 21: 52–57.
  477. Selby R, Geerts WH, Kreder HJ et al (2007) Clinically-Important Venous Thromboembolism (CIVTE) following isolated leg fractures distal to the knee: epidemiology and preventions: the D-KAF (Dalteparin in Knee to Ankle Fracture) trial [abstract]. *J Thromb Haemost*, 5 (suppl 2): O-T-051.
  478. Solis G, Saxby T (2002) Incidence of DVT following surgery of the foot and ankle. *Foot Ankle Int*, 23: 411–414.
  479. Ageno W, Dentali F, Imberti D (2004) A survey of thrombosis prophylaxis use in patients with lower limb fractures. *Thromb Haemost*, 92: 1166–1167.
  480. Geerts WH, Heit JA, Clagett GP et al (2001) Prevention of venous thromboembolism. *Chest*, 119: 132S–175S.
  481. Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. *Cancer*, 89: 640–646.
  482. Chan AT, Atiemo A, Diran LL et al (1999) Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. *J Thromb Thrombolysis*, 8: 139–142.
  483. Walsh DC, Kakkar AK (2001) Thromboembolism in brain tumors. *Curr Opin Pulm Med*, 7: 326–331.
  484. Simanek R, Vormittag R, Hassler M et al (2007) Venous thromboembolism and survival in patients with high-grade glioma. *Neurooncol*, 9: 89–95.
  485. Ruff RL, Posner JB (1983) Incidence and treatment of peripheral venous thrombosis in patients with glioma. *Ann Neurol*, 13: 334–336.
  486. Nurmohamed MT, van Riel AM, Henkens CM et al (1996) Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. *Thromb Haemost*, 75: 233–238.
  487. Wautrecht JC, Macquaire V, Vandesteene A et al (1996) Prevention of deep vein thrombosis in neurosurgical patients with brain tumors: a controlled, randomized study comparing graded compression stockings alone and with intermittent sequential compression: correlation with pre- and postoperative fibrinolysis; preliminary results. *Int Angiol*, 15 (suppl 1): 5–10.
  488. Agnelli G, Piovella F, Buoncristiani P et al (1998) Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med*, 339: 80–85.
  489. Cerrato D, Ariano C, Fiacchino F (1978) Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. *J Neurosurg*, 49: 378–381.
  490. Goldhaber SZ, Dunn K, Gerhard-Herman M et al (2002) Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. *Chest*, 122: 1933–1937.
  491. Macdonald RL, Amidei C, Baron J et al (2003) Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. *Surg Neurol*, 59: 363–374.
  492. Wen DY, Hall WA (1998) Complications of subcutaneous low-dose heparin therapy in neurosurgical patients. *Surg Neurol*, 50: 521–525.
  493. Macdonald RL, Amidei C, Lin G et al (1999) Safety of perioperative subcutaneous heparin for prophylaxis of venous thromboembolism in patients undergoing craniotomy. *Neurosurgery*, 45: 245–251.
  494. Constantini S, Kanner A, Friedman A et al (2001) Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. *J Neurosurg*, 94: 918–921.
  495. Dickinson LD, Miller LD, Patel CP et al (1998) Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. *Neurosurgery*, 43: 1074–1081.
  496. Geerts WH, Code KI, Jay RM et al (1994) A prospective study of venous thromboembolism after major trauma. *N Engl J Med*, 331: 1601–1606.

497. Rogers FB, Cipolle MD, Velmahos G et al (2002) Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST Practice Management Guidelines Work Group. *J Trauma*, 53: 142–164.
498. Nathens AB, McMurray MK, Cuschieri J et al (2007) The practice of venous thromboembolism prophylaxis in the major trauma patient. *J Trauma*, 62: 557–562.
499. Velmahos GC, Kern J, Chan LS et al (2000) Prevention of venous thromboembolism after injury: an evidence-based report; part II. Analysis of risk factors and evaluation of the role of vena caval filters. *J Trauma*, 49: 140–144.
500. Meissner MH, Chandler WL, Elliott JS (2003) Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability? *J Trauma*, 54: 224–231.
501. Knudson MM, Ikossi DG, Khaw L et al (2004) Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. *Ann Surg*; 240: 490–496.
502. Geerts WH, Jay RM, Code KI et al (1996) A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. *N Engl J Med*; 335: 701–707
503. Haentjens P, and the Belgian Fraxiparine Study Group (1996) Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). *Injury*, 27: 385–390.
504. Knudson MM, Morabito D, Paiement GD et al (1996) Use of low molecular weight heparin in preventing thromboembolism in trauma patients. *J Trauma*, 41: 446–459.
505. Cohn SM, Moller BA, Feinstein AJ et al (1999) Prospective trial of low-molecular-weight heparin versus unfractionated heparin in moderately injured patients. *Vasc Surg*, 33: 219–223.
506. Elliott CG, Dudley TM, Egger M et al (1999) Calf-thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep-vein thrombosis after non-lower extremity trauma. *J Trauma*, 47: 25–32.
507. Ginzburg E, Cohn SM, Lopez J et al (2003) Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. *Br J Surg*, 90: 1338–1344.
508. Fuchs S, Heyse T, Rudofsky G et al (2005) Continuous passive motion in the prevention of deep-vein thrombosis: a randomised comparison in trauma patients. *J Bone Joint Surg Br*, 87: 1117–1122.
509. Stannard JP, Lopez-Ben RR, Volgas DA et al (2006) Prophylaxis against deep-vein thrombosis following trauma: a prospective, randomized comparison of mechanical and pharmacologic prophylaxis. *J Bone Joint Surg Am*, 88: 261–266.
510. Knudson MM, Lewis FR, Clinton A et al (1994) Prevention of venous thromboembolism in trauma patients. *J Trauma*, 37: 480–487.
511. Velmahos GC, Kern J, Chan LS et al (2000) Prevention of venous thromboembolism after injury: an evidence-based report; part I. Analysis of risk factors and evaluation of the role of vena caval filters. *J Trauma*, 49: 132–139.
512. Murakami M, McDill TL, Cindrick-Pounds L et al (2003) Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. *J Vasc Surg*, 38: 923–927.
513. Cipolle MD, Wojcik R, Seislove E et al (2002) The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. *J Trauma*, 52: 453–462.
514. Borer DS, Starr AJ, Reinert CM et al (2005) The effect of screening for deep vein thrombosis on the prevalence of pulmonary embolism in patients with fractures of the pelvis or acetabulum: a review of 973 patients. *J Orthop Trauma*, 19: 92–95.
515. Hammers LW, Cohn SM, Brown JM et al (1996) Doppler color flow imaging surveillance of deep vein thrombosis in high-risk trauma patients. *J Ultrasound Med*, 15: 19–24.
516. Spinal Cord Injury Thromboprophylaxis Investigators (2003) Prevention of venous thromboembolism in the acute treatment phase after spinal cord injury: a randomized, multicenter trial comparing low-dose heparin plus intermittent pneumatic compression with enoxaparin. *J Trauma*, 54: 1116–1126.
517. Piotrowski JJ, Alexander JJ, Brandt CP et al (1996) Is deep vein thrombosis surveillance warranted in high-risk trauma patients? *Am J Surg*, 172: 210–213.
518. Brasel KJ, Borgstrom DC, Weigelt JA (1997) Cost-effective prevention of pulmonary embolus in high-risk trauma patients. *J Trauma*, 42: 456–462.
519. Spain DA, Richardson JD, Polk HC et al (1997) Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis? *J Trauma*, 42: 463–469.
520. Schwarcz TH, Quick RC, Minion DJ et al (2001) Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning. *J Vasc Surg*, 34: 447–452.
521. Rogers FB, Shackford SR, Ricci MA et al (1995) Routine prophylactic vena cava filter insertion in severely injured trauma patients decreases the incidence of pulmonary embolism. *J Am Coll Surg*, 180: 641–647.
522. Rodriguez JL, Lopez JM, Proctor MC et al (1996) Early placement of prophylactic vena caval filters in injured patients at high risk for pulmonary embolism. *J Trauma*, 40: 797–802.
523. Carlin AM, Tyburski JG, Wilson RF et al (2002) Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. *Arch Surg*, 137: 521–527.
524. Giannoudis PV, Pountos I, Pape HC et al (2007) Safety and efficacy of vena cava filters in trauma patients. *Injury*, 38: 7–18.
525. Girard TD, Philbrick JT, Fritz Angle J et al (2003) Prophylactic vena cava filters for trauma patients: a systematic review of the literature. *Thromb Res*, 112: 261–267.
526. McMurty AL, Owings JT, Anderson JT et al (1999) Increased use of prophylactic vena cava filters in trauma patients failed to decrease overall incidence of pulmonary embolism. *J Am Coll Surg*, 189: 314–320.
527. Patton JH, Fabian TC, Croce MA et al (1996) Prophylactic Greenfield filters: acute complications and long-term followup. *J Trauma*, 41: 231–236.
528. Decousus H, Leizorovicz A, Parent F et al (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. *N Engl J Med*, 338: 409–415.



529. Blebea J, Wilson R, Waybill P et al (1999) Deep venous thrombosis after percutaneous insertion of vena caval filters. *J Vasc Surg*, 30: 821–828.
530. Karmy-Jones R, Jurkovich GJ, Velmahos GC et al (2007) Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. *J Trauma*, 62: 17–25.
531. Gonzalez RP, Cohen M, Bosarge P et al (2006) Prophylactic inferior vena cava filter insertion for trauma: intensive care unit versus operating room. *Am Surg*, 72: 213–216.
532. Lorch H, Welger D, Wagner V et al (2000) Current practice of temporary vena cava filter insertion: a multicenter registry. *J Vasc Interv Radiol*, 11: 83–88.
533. Offner PJ, Hawkes A, Madayag R et al (2003) The role of temporary inferior vena cava filters in critically ill surgical patients. *Arch Surg*, 138: 591–594.
534. Hoff WS, Hoey BA, Wainwright GA et al (2004) Early experience with retrievable inferior vena cava filters in high-risk trauma patients. *J Am Coll Surg*, 199: 869–874.
535. Morris CS, Rogers FB, Najarian KE et al (2004) Current trends in vena caval filtration with the introduction of a retrievable filter at a level I trauma center. *J Trauma*, 57: 32–36.
536. Antevil JL, Sise MJ, Sack DI et al (2006) Retrievable vena cava filters for preventing pulmonary embolism in trauma patients: a cautionary tale. *J Trauma*, 60: 35–40.
537. Ashley DW, Gamblin TC, Burch ST et al (2001) Accurate deployment of vena cava filters: comparison of intravascular ultrasound and contrast venography. *J Trauma*, 50: 975–981.
538. Conners MS, Becker S, Guzman RJ et al (2002) Duplex scandirected placement of inferior vena cava filters: a five-year institutional experience. *J Vasc Surg*, 35: 286–291.
539. Rosenthal D, Wellons ED, Levitt AB et al (2004) Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. *J Vasc Surg*, 40: 958–964.
540. Sekharan J, Dennis JW, Miranda FE et al (2001) Long-term follow-up of prophylactic Greenfield filters in multisystem trauma patients. *J Trauma*, 51: 1087–1091.
541. Duperier T, Mosenthal A, Swan KG et al (2003) Acute complications associated with Greenfield filter insertion in high-risk trauma patients. *J Trauma*, 54: 545–549.
542. Kaufman JA, Kinney TB, Streiff MB et al (2006) Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. *J Vasc Interv Radiol*, 17: 449–459.
543. Cothren CC, Smith WR, Moore EE et al (2007) Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients. *World J Surg*, 31: 98–104.
544. Allen TL, Carter JL, Morris BJ et al (2005) Retrievable vena cava filters in trauma patients for high-risk prophylaxis and prevention of pulmonary embolism. *Am J Surg*, 189: 656–661.
545. Kirilcuk NN, Hergert EJ, Dicker RA et al (2005) Are temporary inferior vena cava filters really temporary? *Am J Surg*, 190: 858–863.
546. Girard P, Stern JB, Parent F (2002) Medical literature and vena cava filters: so far so weak. *Chest*, 122: 963–967.
547. Maxwell RA, Chavarria-Aguilar M, Cockerham WT et al (2002) Routine prophylactic vena cava filtration is not indicated after acute spinal cord injury. *J Trauma*, 52: 902–906.
548. Norwood SH, McAuley CE, Berne JD et al (2001) A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients. *J Am Coll Surg*, 192: 161–167.
549. Norwood SH, McAuley CE, Berne JD et al (2002) Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. *Arch Surg*, 137: 696–702.
550. Alejandro KV, Acosta JA, Rodriguez PA (2003) Bleeding manifestations after early use of low-molecular-weight heparins in blunt splenic injuries. *Am Surg*, 69: 1006–1009.
551. Bridges GG, Lee MD, Jenkins JK et al (2003) Expedited discharge in trauma patients requiring anticoagulation for deep venous thrombosis prophylaxis: the LEAP Program. *J Trauma*, 54: 232–235.
552. Consortium for Spinal Cord Medicine (1997) Prevention of thromboembolism in spinal cord injury. *J Spinal Cord Med*, 20: 259–283.
553. Waring WP, Karunas RS (1991) Acute spinal cord injuries and the incidence of clinically occurring thromboembolic disease. *Paraplegia*, 29: 8–16.
554. DeVivo MJ, Krause JS, Lammertse DP (1999) Recent trends in mortality and causes of death among persons with spinal cord injury. *Arch Phys Med Rehabil*, 80: 1411–1419.
555. Green D, Hartwig D, Chen D et al (2003) Spinal cord injury risk assessment for thromboembolism (SPIRATE Study). *Am J Phys Med Rehabil*, 82: 950–956.
556. Jones T, Ugalde V, Franks P et al (2005) Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children. *Arch Phys Med Rehabil*, 86: 2240–2247.
557. Green D, Rossi EC, Yao JS et al (1982) Deep vein thrombosis in spinal cord injury: effect of prophylaxis with calf compression, aspirin, and dipyridamole. *Paraplegia*, 20: 227–234.
558. Green D, Lee MY, Ito VY et al (1988) Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. *JAMA*, 260: 1255–1258.
559. Merli GJ, Herbison GJ, Ditunno JF et al (1988) Deep vein thrombosis: prophylaxis in acute spinal cord injured patients. *Arch Phys Med Rehabil*, 69: 661–664.
560. Green D, Lee MY, Lim AC et al (1990) Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin. *Ann Intern Med*, 113: 571–574.
561. Chiou-Tan FY, Garza H, Chan KT et al (2003) Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. *Am J Phys Med Rehabil*, 82: 678–685.
562. Harris S, Chen D, Green D (1996) Enoxaparin for thromboembolism prophylaxis in spinal injury: preliminary report on experience with 105 patients. *Am J Phys Med Rehabil*, 75: 326–327.
563. Hadley MN (2002) Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. *Neurosurgery*, 50 (suppl): S73–S80.
564. Johns JS, Nguyen C, Sing RF (2006) Vena cava filters in spinal cord injuries: evolving technology. *J Spinal Cord Med*, 29: 183–190.

565. Deep K, Jigajinni MV, McLean AN et al (2001) Prophylaxis of thromboembolism in spinal injuries: results of enoxaparin used in 276 patients. *Spinal Cord*, 39: 88–91.
566. Spinal Cord Injury Thromboprophylaxis Investigators (2003) Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin. *J Trauma*, 54: 1111–1115.
567. Kadyan V, Clinchot DM, Mitchell GL et al (2003) Surveillance with duplex ultrasound in traumatic spinal cord injury on initial admission to rehabilitation. *J Spinal Cord Med*, 26: 231–235.
568. Chen D, Apple DF, Hudson LM et al (1999) Medical complications during acute rehabilitation following spinal cord injury: current experience of the Model Systems. *Arch Phys Med Rehabil*, 80: 1397–1401.
569. Aito S, Pieri A, D'Andrea M et al (2002) Primary prevention of deep venous thrombosis and pulmonary embolism in acute spinal cord injured patients. *Spinal Cord*, 40: 300–303.
570. Kadyan V, Clinchot DM, Colachis SC (2004) Cost-effectiveness of duplex ultrasound surveillance in spinal cord injury. *Am J Phys Med Rehabil*, 83: 191–197.
571. Fecher AM, O'Mara MS, Goldfarb IW et al (2004) Analysis of deep vein thrombosis in burn patients. *Burns*, 30: 591–593.
572. Barret JP, Dziewulski PG (2006) Complications of the hypercoagulable status in burn injury. *Burns*, 32: 1005–1008.
573. Zikria J, Ansell J (2009) Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin? *Discov Med*, 8: 196–203.
574. Turpie AG (2009) Direct Factor Xa and direct thrombin inhibitors: a clinical trial update. *Curr Opin Drug Discov Devel*, 12: 497–508.
575. Wittkowsky AK (2009) New oral anticoagulants: a practical guide for clinicians. *J Thromb Thrombolysis*. Nov 4. [Epub ahead of print].
576. Duggan ST, Scott LJ, Plosker GL (2009) Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. *Drugs*, 69: 1829–1851.
577. Samama MM, Gerotziakas GT (2010) Newer anticoagulants in 2009. *J Thromb Thrombolysis*, 29: 92–104.
578. Haas S (2009) New anticoagulants — towards the development of an “ideal” anticoagulant. *Vasa*, 38: 13–29.
579. Jiang J, Hu Y, Zhang J et al (2010) Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban — an oral, direct factor Xa inhibitor — in elderly Chinese subjects. *Thromb Haemost*, 103: 234–241.
580. Eriksson BI, Borris LC, Friedman RJ et al (2008) RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*, 358: 2765–2775.
581. Kakkar AK, Brenner B, Dahl OE et al (2008) RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*, 372: 31–39.
582. Lassen MR, Ageno W, Borris LC et al (2008) RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*, 358: 2776–2786.
583. Turpie AG, Lassen MR, Davidson BL et al (2009) RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*, 373: 1673–1680.

# Skala punktowa dotycząca oceny stopnia zagrożenia rozwojem powikłań zakrzepowo-zatorowych w chirurgii opracowana przez Polską Grupę Roboczą na podstawie skali Josepha Capriniego

Imię i nazwisko pacjenta: \_\_\_\_\_

Każdy czynnik to 1 punkt:

- Wiek 41–60 lat 1
- Mały zabieg chirurgiczny (trwający krócej niż 60 minut) 1
- Duży zabieg chirurgiczny w wywiadzie (w ciągu ostatniego miesiąca) 1
- Żyłaki kończyn dolnych (C<sub>3</sub>–C<sub>6</sub>) 1
- Choroby zapalne jelit w wywiadzie 1
- Obrzęki kończyn dolnych 1
- Otyłość (BMI > 30 kg/m<sup>2</sup>) 1
- Ostry zawał serca (w ciągu ostatniego miesiąca) 1
- Zastoinowa niewydolność serca (zaostrenie w ciągu ostatniego miesiąca) 1
- Ciężkie choroby płuc, w tym zapalenie płuc (w ciągu ostatniego miesiąca) 1
- Przewlekła obturacyjna choroba płuc (POChP) 1
- Obciążenia internistyczne — unieruchomienie w łóżku 1
- Unieruchomienie kończyny dolnej w gipsie lub ortezie 1
- Cewnik w żyłę centralnej 1
- Przebyte zapalenie zakrzepowe żył powierzchownych 1

Każdy czynnik to 2 punkty:

- Wiek 60–74 lat 2
- Duży zabieg chirurgiczny (trwający dłużej niż 60 minut) 2
- Zabieg artroskopowy 2
- Chirurgia laparoskopowa (zabieg trwający dłużej niż 60 minut) 2
- Przebyta choroba nowotworowa 2
- Posocznica (w ciągu ostatniego miesiąca) 2
- Duża otyłość (BMI > 40 kg/m<sup>2</sup>) 2
- Trombofilia mniejszego ryzyka (heterozygotyczna postać czynnika V Leiden lub mutacji genu protrombiny, wzrost aktywności czynnika VIII > 150%) 2
- Zakrzepica żył głębokich lub zator tętnicy płucnej w wywiadzie rodzinnym 2

Każdy czynnik to 3 punkty:

- Wiek powyżej 75 lat 3
- Duży zabieg chirurgiczny (trwający dłużej niż 3 godziny) 3
- BMI > 50 kg/m<sup>2</sup> 3
- Przebyta zakrzepica żył głębokich lub zator tętnicy płucnej 3
- Trombofilia większego ryzyka (homozygotyczna postać czynnika V Leiden lub mutacji 20210A genu protrombiny, niedobór AT, białka C, białka S, obecność przeciwciał antyfosfolipidowych) 3
- Trombofilia złożona (współistnienie genetycznie uwarunkowanych defektów) 3
- Małopłytkowość indukowana heparyną (HIT) 3

Każdy czynnik to 5 punktów:

- Protezooplastyka dużych stawów kończyn dolnych 5
- Złamanie biodra, miednicy lub kończyny dolnej (w ciągu ostatniego miesiąca) 5
- Udar niedokrwieny mózgu (w ciągu ostatniego miesiąca) 5
- Uraz wielonarządowy (w ciągu ostatniego miesiąca) 5
- Ostry uraz rdzenia kręgowego z porażeniem (w ciągu ostatniego miesiąca) 5
- Zakrzepica żył głębokich lub zator tętnicy płucnej w trakcie leczenia 5
- Reoperacja 5
- Zabieg chirurgiczny u chorego z aktywną chorobą nowotworową 5

Czynniki ryzyka, które należy uwzględnić u kobiet.  
Każdy czynnik to 1 punkt:

- W wywiadzie:
- wewnątrzmaciczne obumarcie płodu 1
  - poronienia nawykowe (> 3) 1
  - przedwczesny poród z nadciśnieniem indukowanym ciążą 1
  - wewnątrzmaciczne zahamowanie wzrostu płodu 1

Każdy czynnik to 2 punkty:

- Antykoncepcja hormonalna lub hormonalna terapia zastępcza (HTZ) 2
- Ciąża lub połóg (do 6 tygodni) 2

## Ocena ryzyka rozwoju powikłań zakrzepowo-zatorowych

### 0–1 punktów: małe ryzyko

Rekomendacje: wczesne uruchomienie chorego

### 2 punkty: umiarkowane ryzyko

Rekomendacje: zastosowanie profilaktyki farmakologicznej zgodnie ze wskazaniem i zaleceniem producenta

### 3 punkty: duże ryzyko

Rekomendacje: zastosowanie profilaktyki farmakologicznej zgodnie z zaleceniem producenta. W razie stwierdzenia przeciwwskazań do profilaktyki farmakologicznej zaleca się stosowanie profilaktyki metodami fizykalnymi

### ≥ 4 punktów

Rekomendacje: łączenie profilaktyki farmakologicznej i przerywanego pneumatycznego ucisku kończyny dolnych

**Punktacja i przyporządkowanie uzyskanej sumy  
do grupy ryzyka oraz rekomendacje Polskiej Grupy Roboczej**

W każdym przypadku przed zastosowaniem profilaktyki przeciwzakrzepowej należy przeanalizować ewentualne przeciwwskazania. W przypadku przeciwwskazań do profilaktyki z wykorzystaniem metod farmakologicznych zaleca się stosowanie metod fizykalnych.

Rekomenduje się rozważenie przedłużenia do 28 dni pierwotnej profilaktyki przeciwzakrzepowej z zastosowaniem heparyny drobnocząsteczkowej podawanej podskórnie 1 raz na dobę u wybranych pacjentów po wypisie ze szpitala oraz u chorych po zabiegu operacyjnym z powodu nowotworu złośliwego lub zabiegu z zakresu chirurgii wysokiego ryzyka żyłnej choroby zakrzepowo-zatorowej, o ile nie wiąże się to z nieakceptowalnie wysokim ryzykiem powikłań krwotocznych.

**Skład Polskiej Grupy Roboczej**

**Przewodniczący:** prof. Witold Tomkowski

**Sekretarz:** dr Paweł Kuca

**Członkowie (w kolejności alfabetycznej):**

prof. Piotr Andziak  
prof. Adam Dzik  
prof. Rafał Niżankowski  
prof. Walerian Staszkiwicz  
doc. Jerzy Windyga  
prof. Jacek Wroński

**Członkowie korespondencyjni (w kolejności alfabetycznej):**

prof. Janusz Andres  
prof. Jacek Imiela  
prof. Arkadiusz Jawień  
prof. Jan Kulig  
doc. Tomasz Urbanek

**Uwaga!** Literatura przedmiotu znajduje się w artykule *Skala punktowa opracowana przez Polską Grupę Roboczą na podstawie skali Josepha Capriniego dotycząca oceny stopnia zagrożenia rozwoju powikłań zakrzepowo-zatorowych w chirurgii*, Acta Angiologica 2011; 17: 49–74.